https://spypharm.com/rss/category/life-sciences SpyPharm | Pharmaceutical News, Developments & Trends & : Life Sciences en Copyright 2023 Spypharm & All Rights Reserved. https://spypharm.com/roche-partners-with-transcription-factor-pioneer-flare-in-over-18b-cancer-deal https://spypharm.com/roche-partners-with-transcription-factor-pioneer-flare-in-over-18b-cancer-deal Wed, 20 Nov 2024 06:00:07 -0500 spectro https://spypharm.com/fda-to-lift-hold-over-novavax-flu-shot-program https://spypharm.com/fda-to-lift-hold-over-novavax-flu-shot-program Sat, 16 Nov 2024 06:00:12 -0500 spectro https://spypharm.com/jj-medtech-gets-fda-nod-for-varipulse-pfa-system https://spypharm.com/jj-medtech-gets-fda-nod-for-varipulse-pfa-system Sat, 16 Nov 2024 06:00:09 -0500 spectro https://spypharm.com/bad-news-for-abbvie-as-emraclidine-fails-to-perform-in-trials https://spypharm.com/bad-news-for-abbvie-as-emraclidine-fails-to-perform-in-trials Sat, 16 Nov 2024 06:00:07 -0500 spectro https://spypharm.com/improving-life-science-rd-outcomes-with-ai https://spypharm.com/improving-life-science-rd-outcomes-with-ai Sun, 10 Nov 2024 06:00:07 -0500 spectro https://spypharm.com/novo-scores-license-to-use-ascendis-transcon-platform-for-285-million https://spypharm.com/novo-scores-license-to-use-ascendis-transcon-platform-for-285-million Wed, 06 Nov 2024 06:00:09 -0500 spectro https://spypharm.com/astrazenecas-obesity-pill-shows-positive-results-in-early-trial https://spypharm.com/astrazenecas-obesity-pill-shows-positive-results-in-early-trial Wed, 06 Nov 2024 06:00:06 -0500 spectro https://spypharm.com/after-roche-and-takeda-novartis-steps-into-the-molecular-glue-space https://spypharm.com/after-roche-and-takeda-novartis-steps-into-the-molecular-glue-space Sat, 02 Nov 2024 04:00:14 -0400 spectro https://spypharm.com/abbvie-completes-14b-purchase-of-aliada https://spypharm.com/abbvie-completes-14b-purchase-of-aliada Sat, 02 Nov 2024 04:00:12 -0400 spectro https://spypharm.com/astellas-and-europe-clash-over-approval-of-geographic-atrophy-drug-izervay https://spypharm.com/astellas-and-europe-clash-over-approval-of-geographic-atrophy-drug-izervay Sat, 02 Nov 2024 04:00:09 -0400 spectro https://spypharm.com/apellis-and-novartis-both-target-rare-kidney-diseases-with-new-drugs https://spypharm.com/apellis-and-novartis-both-target-rare-kidney-diseases-with-new-drugs Sat, 02 Nov 2024 04:00:07 -0400 spectro https://spypharm.com/merck-gileads-combined-hiv-treatment-sunlenca-shows-positive-results-in-mid-phase-clinical-trial https://spypharm.com/merck-gileads-combined-hiv-treatment-sunlenca-shows-positive-results-in-mid-phase-clinical-trial Tue, 29 Oct 2024 04:00:14 -0400 spectro https://spypharm.com/arcus-hif-2a-inhibitor-shows-positive-response-rate-in-study https://spypharm.com/arcus-hif-2a-inhibitor-shows-positive-response-rate-in-study Tue, 29 Oct 2024 04:00:11 -0400 spectro https://spypharm.com/marinus-to-cut-workforce-and-explore-options-after-ztalmy-trial-setback https://spypharm.com/marinus-to-cut-workforce-and-explore-options-after-ztalmy-trial-setback Tue, 29 Oct 2024 04:00:09 -0400 spectro https://spypharm.com/gsk-responds-to-pfizers-rsv-approval-with-data-aiming-for-similar-approval-in-younger-adults https://spypharm.com/gsk-responds-to-pfizers-rsv-approval-with-data-aiming-for-similar-approval-in-younger-adults Tue, 29 Oct 2024 04:00:06 -0400 spectro https://spypharm.com/wisp-launches-weight-care-vertical-for-women-with-hormonal-imbalances https://spypharm.com/wisp-launches-weight-care-vertical-for-women-with-hormonal-imbalances Wed, 23 Oct 2024 04:00:11 -0400 spectro https://spypharm.com/novartis-strikes-11b-deal-with-chinas-baiyu-for-a-small-molecule-cancer-contender https://spypharm.com/novartis-strikes-11b-deal-with-chinas-baiyu-for-a-small-molecule-cancer-contender Wed, 23 Oct 2024 04:00:07 -0400 spectro https://spypharm.com/new-drug-roche-to-enter-breast-cancer-therapy-field https://spypharm.com/new-drug-roche-to-enter-breast-cancer-therapy-field Thu, 17 Oct 2024 04:00:05 -0400 spectro https://spypharm.com/developments-in-rna-research-win-nobel-prizes-for-the-second-consecutive-year https://spypharm.com/developments-in-rna-research-win-nobel-prizes-for-the-second-consecutive-year Sun, 13 Oct 2024 04:00:13 -0400 spectro https://spypharm.com/talk-of-vaccine-schedule-revision-amidst-research-showing-waning-efficacy-of-gsks-rsv-vaccine https://spypharm.com/talk-of-vaccine-schedule-revision-amidst-research-showing-waning-efficacy-of-gsks-rsv-vaccine Sun, 13 Oct 2024 04:00:10 -0400 spectro https://spypharm.com/maven-clinic-receives-125-million-to-fund-technology-and-value-based-treatment https://spypharm.com/maven-clinic-receives-125-million-to-fund-technology-and-value-based-treatment Sun, 13 Oct 2024 04:00:08 -0400 spectro https://spypharm.com/the-medical-device-sectors-surging-regulatory-burden-how-are-suppliers-coping https://spypharm.com/the-medical-device-sectors-surging-regulatory-burden-how-are-suppliers-coping Sun, 13 Oct 2024 04:00:05 -0400 spectro https://spypharm.com/scholar-rocks-phase-3-sma-trial-achieves-success https://spypharm.com/scholar-rocks-phase-3-sma-trial-achieves-success Fri, 11 Oct 2024 04:00:08 -0400 spectro https://spypharm.com/jj-halts-late-stage-trial-for-bladder-cancer-prospect https://spypharm.com/jj-halts-late-stage-trial-for-bladder-cancer-prospect Fri, 11 Oct 2024 04:00:05 -0400 spectro https://spypharm.com/editas-sells-rights-to-a-licensing-agreement-in-a-57-million-deal https://spypharm.com/editas-sells-rights-to-a-licensing-agreement-in-a-57-million-deal Wed, 09 Oct 2024 04:00:07 -0400 spectro https://spypharm.com/fda-authorizes-the-first-novel-schizophrenia-therapy-in-decades https://spypharm.com/fda-authorizes-the-first-novel-schizophrenia-therapy-in-decades Thu, 03 Oct 2024 04:00:14 -0400 spectro https://spypharm.com/astrazeneca-expands-ai-powered-immuno-oncology-research-partnership-with-immunai https://spypharm.com/astrazeneca-expands-ai-powered-immuno-oncology-research-partnership-with-immunai Thu, 03 Oct 2024 04:00:11 -0400 spectro https://spypharm.com/abbvies-parkinsons-drug-meets-phase-3-trial-goal https://spypharm.com/abbvies-parkinsons-drug-meets-phase-3-trial-goal Thu, 03 Oct 2024 04:00:09 -0400 spectro https://spypharm.com/repair-biotechnologies-to-leverage-genevant-sciences-lnp-technology-for-atherosclerosis-treatment https://spypharm.com/repair-biotechnologies-to-leverage-genevant-sciences-lnp-technology-for-atherosclerosis-treatment Thu, 03 Oct 2024 04:00:06 -0400 spectro https://spypharm.com/biogen-and-ucbs-lupus-drug-achieves-primary-objective-in-late-stage-trial https://spypharm.com/biogen-and-ucbs-lupus-drug-achieves-primary-objective-in-late-stage-trial Fri, 27 Sep 2024 04:00:13 -0400 spectro https://spypharm.com/experimental-pill-by-novo-nordisk-shown-to-have-side-effects-in-trial https://spypharm.com/experimental-pill-by-novo-nordisk-shown-to-have-side-effects-in-trial Fri, 27 Sep 2024 04:00:11 -0400 spectro https://spypharm.com/vicebio-raises-100-million-in-series-b-funding-to-advance-rsv-combination-vaccine-through-phase-i https://spypharm.com/vicebio-raises-100-million-in-series-b-funding-to-advance-rsv-combination-vaccine-through-phase-i Fri, 27 Sep 2024 04:00:08 -0400 spectro https://spypharm.com/picnichealth-launches-new-service-bringing-observational-clinical-trials-to-the-virtual-realm https://spypharm.com/picnichealth-launches-new-service-bringing-observational-clinical-trials-to-the-virtual-realm Fri, 27 Sep 2024 04:00:06 -0400 spectro https://spypharm.com/iteos-drug-in-combination-with-gsks-jemperli-shows-positive-response-in-lung-cancer-treatment https://spypharm.com/iteos-drug-in-combination-with-gsks-jemperli-shows-positive-response-in-lung-cancer-treatment Thu, 19 Sep 2024 04:00:08 -0400 spectro https://spypharm.com/long-term-immunotherapy-benefits-for-melanoma-shown-in-ten-year-survival-data https://spypharm.com/long-term-immunotherapy-benefits-for-melanoma-shown-in-ten-year-survival-data Thu, 19 Sep 2024 04:00:06 -0400 spectro https://spypharm.com/terns-oral-glp-1-achieves-5-weight-reduction-within-one-month-at-the-highest-dose https://spypharm.com/terns-oral-glp-1-achieves-5-weight-reduction-within-one-month-at-the-highest-dose Fri, 13 Sep 2024 04:00:19 -0400 spectro https://spypharm.com/relay-wins-early-on-breast-cancer-arranges-crucial-trial-against-truqap-from-astrazeneca https://spypharm.com/relay-wins-early-on-breast-cancer-arranges-crucial-trial-against-truqap-from-astrazeneca Fri, 13 Sep 2024 04:00:17 -0400 spectro https://spypharm.com/viridian-drug-successfully-meets-study-objectives-as-treatment-for-thyroid-eye-disease https://spypharm.com/viridian-drug-successfully-meets-study-objectives-as-treatment-for-thyroid-eye-disease Fri, 13 Sep 2024 04:00:14 -0400 spectro https://spypharm.com/brightflow-sas-nabs-18m-for-heart-failure-solution https://spypharm.com/brightflow-sas-nabs-18m-for-heart-failure-solution Fri, 13 Sep 2024 04:00:12 -0400 spectro https://spypharm.com/gilead-and-ai-drug-discovery-company-genesis-sign-35-million-partnership https://spypharm.com/gilead-and-ai-drug-discovery-company-genesis-sign-35-million-partnership Fri, 13 Sep 2024 04:00:09 -0400 spectro https://spypharm.com/eli-lilly-sees-second-round-of-positive-data-on-weekly-insulin-candidate https://spypharm.com/eli-lilly-sees-second-round-of-positive-data-on-weekly-insulin-candidate Fri, 13 Sep 2024 04:00:06 -0400 spectro https://spypharm.com/gsks-asthma-drug-meets-primary-endpoint-in-phase-3-trial https://spypharm.com/gsks-asthma-drug-meets-primary-endpoint-in-phase-3-trial Wed, 11 Sep 2024 04:00:06 -0400 spectro https://spypharm.com/onward-awarded-11m-grant-from-the-christopher-dana-reeve-foundation-to-advance-bci-research https://spypharm.com/onward-awarded-11m-grant-from-the-christopher-dana-reeve-foundation-to-advance-bci-research Sat, 07 Sep 2024 04:00:12 -0400 spectro https://spypharm.com/illumina-gets-favorable-decision-regarding-grail-acquisition https://spypharm.com/illumina-gets-favorable-decision-regarding-grail-acquisition Sat, 07 Sep 2024 04:00:09 -0400 spectro https://spypharm.com/sanofis-tolebrutinib-faces-defeat-in-2-out-of-3-phase-3-ms-trials https://spypharm.com/sanofis-tolebrutinib-faces-defeat-in-2-out-of-3-phase-3-ms-trials Sat, 07 Sep 2024 04:00:07 -0400 spectro https://spypharm.com/phase-23-of-athira-trial-for-alzheimers-fails https://spypharm.com/phase-23-of-athira-trial-for-alzheimers-fails Sat, 07 Sep 2024 04:00:05 -0400 spectro https://spypharm.com/allist-secures-leading-role-in-chinas-kras-inhibitor-market-with-21m-jacobio-deal https://spypharm.com/allist-secures-leading-role-in-chinas-kras-inhibitor-market-with-21m-jacobio-deal Tue, 03 Sep 2024 04:00:08 -0400 spectro https://spypharm.com/emergent-bios-smallpox-vaccine-gains-fda-approval-for-mpox https://spypharm.com/emergent-bios-smallpox-vaccine-gains-fda-approval-for-mpox Tue, 03 Sep 2024 04:00:06 -0400 spectro https://spypharm.com/siemens-healthineers-to-acquire-novartis-european-radiodiagnostic-production-network https://spypharm.com/siemens-healthineers-to-acquire-novartis-european-radiodiagnostic-production-network Sun, 01 Sep 2024 04:00:06 -0400 spectro https://spypharm.com/bavarian-nordic-receives-mpox-vaccine-green-light-from-singapore https://spypharm.com/bavarian-nordic-receives-mpox-vaccine-green-light-from-singapore Fri, 30 Aug 2024 04:00:08 -0400 spectro https://spypharm.com/mckesson-invests-25b-to-acquire-majority-stake-in-florida-based-community-oncology https://spypharm.com/mckesson-invests-25b-to-acquire-majority-stake-in-florida-based-community-oncology Fri, 30 Aug 2024 04:00:05 -0400 spectro https://spypharm.com/ucb-offloads-neurology-and-allergy-meds-in-china-for-nearly-700m https://spypharm.com/ucb-offloads-neurology-and-allergy-meds-in-china-for-nearly-700m Wed, 28 Aug 2024 04:00:09 -0400 spectro https://spypharm.com/germany-to-provide-100000-mpox-vaccine-doses-to-combat-outbreak-in-africa https://spypharm.com/germany-to-provide-100000-mpox-vaccine-doses-to-combat-outbreak-in-africa Wed, 28 Aug 2024 04:00:06 -0400 spectro https://spypharm.com/pathalys-raises-105-million-in-series-b-to-prepare-renal-disease-drug-for-fda-approval https://spypharm.com/pathalys-raises-105-million-in-series-b-to-prepare-renal-disease-drug-for-fda-approval Sat, 24 Aug 2024 04:00:09 -0400 spectro https://spypharm.com/eli-lillys-weight-loss-drug-significantly-reduces-diabetes-risk-in-long-term-study https://spypharm.com/eli-lillys-weight-loss-drug-significantly-reduces-diabetes-risk-in-long-term-study Sat, 24 Aug 2024 04:00:06 -0400 spectro https://spypharm.com/ascendis-receives-a-grudging-fda-approval-for-yorvipath-a-hormone-replacement-treatment https://spypharm.com/ascendis-receives-a-grudging-fda-approval-for-yorvipath-a-hormone-replacement-treatment Sun, 18 Aug 2024 04:00:07 -0400 spectro https://spypharm.com/pfizer-releases-abrysvo-for-rsv-top-line-results-in-immunocompromised-adults https://spypharm.com/pfizer-releases-abrysvo-for-rsv-top-line-results-in-immunocompromised-adults Fri, 16 Aug 2024 04:00:08 -0400 spectro https://spypharm.com/us-fda-rejects-lykos-mdma-based-ptsd-therapy https://spypharm.com/us-fda-rejects-lykos-mdma-based-ptsd-therapy Fri, 16 Aug 2024 04:00:06 -0400 spectro https://spypharm.com/fda-approves-ascendis-yorvipath-for-the-treatment-of-hypoparathyroidism https://spypharm.com/fda-approves-ascendis-yorvipath-for-the-treatment-of-hypoparathyroidism Wed, 14 Aug 2024 04:00:05 -0400 spectro https://spypharm.com/voranigo-receives-fda-clearance-as-a-brain-tumor-inhibitor https://spypharm.com/voranigo-receives-fda-clearance-as-a-brain-tumor-inhibitor Sat, 10 Aug 2024 04:00:14 -0400 spectro https://spypharm.com/novo-nordisk-says-goodbye-to-glp-1gip-mash-prospect https://spypharm.com/novo-nordisk-says-goodbye-to-glp-1gip-mash-prospect Sat, 10 Aug 2024 04:00:12 -0400 spectro https://spypharm.com/elon-musk-announces-neuralinks-second-brain-computer-chip-implantation-in-a-patient https://spypharm.com/elon-musk-announces-neuralinks-second-brain-computer-chip-implantation-in-a-patient Sat, 10 Aug 2024 04:00:10 -0400 spectro https://spypharm.com/vertex-crisprs-casgevy-given-the-green-light-by-nice https://spypharm.com/vertex-crisprs-casgevy-given-the-green-light-by-nice Sat, 10 Aug 2024 04:00:05 -0400 spectro https://spypharm.com/cvc-capital-to-pay-925-million-to-mallinckrodt-for-sale-of-therakos-business-unit https://spypharm.com/cvc-capital-to-pay-925-million-to-mallinckrodt-for-sale-of-therakos-business-unit Thu, 08 Aug 2024 04:00:05 -0400 spectro https://spypharm.com/agios-fails-to-reach-primary-objective-in-pediatric-study https://spypharm.com/agios-fails-to-reach-primary-objective-in-pediatric-study Tue, 06 Aug 2024 04:00:06 -0400 spectro https://spypharm.com/alpha-cognitions-alpha-1062-becomes-the-second-oral-fda-approved-treatment-for-alzheimers-disease https://spypharm.com/alpha-cognitions-alpha-1062-becomes-the-second-oral-fda-approved-treatment-for-alzheimers-disease Fri, 02 Aug 2024 04:00:04 -0400 spectro https://spypharm.com/edwards-acquires-2-firms-in-deals-totaling-12-billion https://spypharm.com/edwards-acquires-2-firms-in-deals-totaling-12-billion Wed, 31 Jul 2024 04:00:10 -0400 spectro https://spypharm.com/europe-risks-a-setback-for-eisai-and-biogens-alzheimers-medication https://spypharm.com/europe-risks-a-setback-for-eisai-and-biogens-alzheimers-medication Wed, 31 Jul 2024 04:00:07 -0400 spectro https://spypharm.com/ventyxs-crohns-disease-medicine-fails-to-make-a-mark-in-phase-2-trial https://spypharm.com/ventyxs-crohns-disease-medicine-fails-to-make-a-mark-in-phase-2-trial Wed, 31 Jul 2024 04:00:05 -0400 spectro https://spypharm.com/netherlands-to-get-eu-green-light-for-22b-nuclear-reactor-aid https://spypharm.com/netherlands-to-get-eu-green-light-for-22b-nuclear-reactor-aid Mon, 29 Jul 2024 04:00:08 -0400 spectro https://spypharm.com/pfizers-hemophilia-gene-treatment-reaches-late-stage-research-target https://spypharm.com/pfizers-hemophilia-gene-treatment-reaches-late-stage-research-target Mon, 29 Jul 2024 04:00:05 -0400 spectro https://spypharm.com/brazil-curbs-poultry-exports-amid-newcastle-viral-disease https://spypharm.com/brazil-curbs-poultry-exports-amid-newcastle-viral-disease Sat, 27 Jul 2024 04:00:12 -0400 spectro https://spypharm.com/ionis-plans-to-advance-angelman-drug-biogen-with-clinical-success https://spypharm.com/ionis-plans-to-advance-angelman-drug-biogen-with-clinical-success Sat, 27 Jul 2024 04:00:10 -0400 spectro https://spypharm.com/astrazeneca-grows-egfr-portfolio-with-45m-pinetree-deal https://spypharm.com/astrazeneca-grows-egfr-portfolio-with-45m-pinetree-deal Sat, 27 Jul 2024 04:00:08 -0400 spectro https://spypharm.com/rsv-antibody-passes-final-trials-in-win-for-merck https://spypharm.com/rsv-antibody-passes-final-trials-in-win-for-merck Sat, 27 Jul 2024 04:00:05 -0400 spectro https://spypharm.com/scorpion-secures-150m-in-series-c-funding-to-expand-cancer-pipeline-clinical-plans https://spypharm.com/scorpion-secures-150m-in-series-c-funding-to-expand-cancer-pipeline-clinical-plans Fri, 19 Jul 2024 04:00:20 -0400 spectro https://spypharm.com/house-committee-orders-fda-to-halt-regulation-governing-lab-developed-tests https://spypharm.com/house-committee-orders-fda-to-halt-regulation-governing-lab-developed-tests Fri, 19 Jul 2024 04:00:18 -0400 spectro https://spypharm.com/sionna-pens-deal-with-abbvie-for-cystic-fibrosis-drugs https://spypharm.com/sionna-pens-deal-with-abbvie-for-cystic-fibrosis-drugs Fri, 19 Jul 2024 04:00:15 -0400 spectro https://spypharm.com/meilleur-technologies-creator-of-pet-tests-for-alzheimers-disease-acquired-by-lantheus https://spypharm.com/meilleur-technologies-creator-of-pet-tests-for-alzheimers-disease-acquired-by-lantheus Fri, 19 Jul 2024 04:00:13 -0400 spectro https://spypharm.com/covid-symptoms-prevented-by-new-drug-used-on-mice-no-risk-of-resistance https://spypharm.com/covid-symptoms-prevented-by-new-drug-used-on-mice-no-risk-of-resistance Fri, 19 Jul 2024 04:00:10 -0400 spectro https://spypharm.com/backed-by-novo-holdings-asceneuron-raises-100-million-in-quest-for-alzheimers-cure https://spypharm.com/backed-by-novo-holdings-asceneuron-raises-100-million-in-quest-for-alzheimers-cure Fri, 19 Jul 2024 04:00:08 -0400 spectro https://spypharm.com/autoimmune-stricken-patients-respond-to-allogeneic-car-t-treatment https://spypharm.com/autoimmune-stricken-patients-respond-to-allogeneic-car-t-treatment Fri, 19 Jul 2024 04:00:05 -0400 spectro https://spypharm.com/myricx-bio-raises-114m-in-series-a-funding-to-advance-nmti-adcs-development https://spypharm.com/myricx-bio-raises-114m-in-series-a-funding-to-advance-nmti-adcs-development Thu, 11 Jul 2024 04:00:11 -0400 spectro https://spypharm.com/beacon-raises-170m-series-b-for-eye-disease-candidates https://spypharm.com/beacon-raises-170m-series-b-for-eye-disease-candidates Thu, 11 Jul 2024 04:00:09 -0400 spectro https://spypharm.com/after-a-two-year-recall-roche-set-to-relaunch-eye-implant-medication-susvimo https://spypharm.com/after-a-two-year-recall-roche-set-to-relaunch-eye-implant-medication-susvimo Thu, 11 Jul 2024 04:00:07 -0400 spectro https://spypharm.com/mesoblast-resubmits-bla-for-ryoncil-approval https://spypharm.com/mesoblast-resubmits-bla-for-ryoncil-approval Thu, 11 Jul 2024 04:00:04 -0400 spectro https://spypharm.com/roche-stops-lung-cancer-immunotherapy-trial-in-newest-disappointment https://spypharm.com/roche-stops-lung-cancer-immunotherapy-trial-in-newest-disappointment Tue, 09 Jul 2024 04:00:07 -0400 spectro https://spypharm.com/pentixapharm-acquires-glycotope-for-its-target-discovery-business https://spypharm.com/pentixapharm-acquires-glycotope-for-its-target-discovery-business Tue, 09 Jul 2024 04:00:04 -0400 spectro https://spypharm.com/european-regulatory-agency-gives-astrazenecas-covid-19-preventative-drug-thumbs-up https://spypharm.com/european-regulatory-agency-gives-astrazenecas-covid-19-preventative-drug-thumbs-up Fri, 05 Jul 2024 04:00:09 -0400 spectro https://spypharm.com/sanofis-dupixent-injectable-approved-by-the-eu-to-treat-chronic-lung-disease https://spypharm.com/sanofis-dupixent-injectable-approved-by-the-eu-to-treat-chronic-lung-disease Fri, 05 Jul 2024 04:00:06 -0400 spectro https://spypharm.com/deal-on-cancer-adc-gets-canceled-by-eisai-and-bristol-myers https://spypharm.com/deal-on-cancer-adc-gets-canceled-by-eisai-and-bristol-myers Fri, 05 Jul 2024 04:00:03 -0400 spectro https://spypharm.com/novartis-moderna-gsk-and-others-team-up-with-slope-in-a-new-biospecimen-consortium https://spypharm.com/novartis-moderna-gsk-and-others-team-up-with-slope-in-a-new-biospecimen-consortium Mon, 01 Jul 2024 04:00:11 -0400 spectro https://spypharm.com/cdc-immunization-advisors-vote-to-reduce-recommendations-for-rsv-vaccination https://spypharm.com/cdc-immunization-advisors-vote-to-reduce-recommendations-for-rsv-vaccination Mon, 01 Jul 2024 04:00:08 -0400 spectro https://spypharm.com/ai-firm-formation-bags-372-series-d-funding https://spypharm.com/ai-firm-formation-bags-372-series-d-funding Mon, 01 Jul 2024 04:00:05 -0400 spectro https://spypharm.com/novo-creates-a-favorable-picture-for-the-medicine-used-to-prevent-hemophilia https://spypharm.com/novo-creates-a-favorable-picture-for-the-medicine-used-to-prevent-hemophilia Thu, 27 Jun 2024 04:00:16 -0400 spectro https://spypharm.com/astrazenecas-imfinzi-unsuccessful-in-late-stage-trial-for-specific-lung-cancers https://spypharm.com/astrazenecas-imfinzi-unsuccessful-in-late-stage-trial-for-specific-lung-cancers Thu, 27 Jun 2024 04:00:14 -0400 spectro https://spypharm.com/novos-wegovy-leads-to-women-losing-more-weight-than-men https://spypharm.com/novos-wegovy-leads-to-women-losing-more-weight-than-men Thu, 27 Jun 2024 04:00:11 -0400 spectro https://spypharm.com/rsv-vaccine-race-takes-a-turn-as-pfizer-beats-gsk-for-uk-contract https://spypharm.com/rsv-vaccine-race-takes-a-turn-as-pfizer-beats-gsk-for-uk-contract Thu, 27 Jun 2024 04:00:09 -0400 spectro https://spypharm.com/novo-nordisk-planning-huge-41b-plant-in-nc-for-ozempic-production https://spypharm.com/novo-nordisk-planning-huge-41b-plant-in-nc-for-ozempic-production Thu, 27 Jun 2024 04:00:06 -0400 spectro https://spypharm.com/disappointing-phase-3-trial-results-cause-merck-to-shelve-head-and-neck-cancer-drug https://spypharm.com/disappointing-phase-3-trial-results-cause-merck-to-shelve-head-and-neck-cancer-drug Thu, 27 Jun 2024 04:00:03 -0400 spectro https://spypharm.com/hikma-shells-out-185-million-to-purchase-xellias-us-assets https://spypharm.com/hikma-shells-out-185-million-to-purchase-xellias-us-assets Tue, 25 Jun 2024 04:00:09 -0400 spectro https://spypharm.com/after-torrent-takeda-partners-with-cipla-and-sun-pharma-to-commercialize-gastro-drug-vonoprazan https://spypharm.com/after-torrent-takeda-partners-with-cipla-and-sun-pharma-to-commercialize-gastro-drug-vonoprazan Tue, 25 Jun 2024 04:00:06 -0400 spectro https://spypharm.com/alnylam-reports-successful-results-in-highly-anticipated-heart-drug-study https://spypharm.com/alnylam-reports-successful-results-in-highly-anticipated-heart-drug-study Tue, 25 Jun 2024 04:00:03 -0400 spectro https://spypharm.com/according-to-research-gileads-long-acting-hiv-medication-is-superior-to-truvada https://spypharm.com/according-to-research-gileads-long-acting-hiv-medication-is-superior-to-truvada Sun, 23 Jun 2024 04:00:07 -0400 spectro https://spypharm.com/health-tech-startup-evidation-opens-up-its-symptom-logging-app-to-track-migraine-discomfort https://spypharm.com/health-tech-startup-evidation-opens-up-its-symptom-logging-app-to-track-migraine-discomfort Sun, 23 Jun 2024 04:00:04 -0400 spectro https://spypharm.com/fda-expert-panel-backs-eli-lillys-alzheimers-drug-donanemab https://spypharm.com/fda-expert-panel-backs-eli-lillys-alzheimers-drug-donanemab Sat, 15 Jun 2024 04:00:11 -0400 spectro https://spypharm.com/ipsen-and-genfit-receive-accelerated-fda-nod-for-liver-disorder-drug https://spypharm.com/ipsen-and-genfit-receive-accelerated-fda-nod-for-liver-disorder-drug Sat, 15 Jun 2024 04:00:09 -0400 spectro https://spypharm.com/phase-3-trial-results-for-loqtorzi-show-positive-results-in-advanced-hepatocellular-carcinoma-patients https://spypharm.com/phase-3-trial-results-for-loqtorzi-show-positive-results-in-advanced-hepatocellular-carcinoma-patients Sat, 15 Jun 2024 04:00:07 -0400 spectro https://spypharm.com/pfizers-phase-3-trial-for-gene-therapy-in-boys-with-duchenne-muscular-dystrophy-fails-to-show-functional-improvement https://spypharm.com/pfizers-phase-3-trial-for-gene-therapy-in-boys-with-duchenne-muscular-dystrophy-fails-to-show-functional-improvement Sat, 15 Jun 2024 04:00:04 -0400 spectro https://spypharm.com/fda-considers-monthly-dosing-for-alzheimers-drug-leqembi https://spypharm.com/fda-considers-monthly-dosing-for-alzheimers-drug-leqembi Thu, 13 Jun 2024 04:00:06 -0400 spectro https://spypharm.com/boehringers-ingelheims-survodutide-shows-liver-fibrosis-improvement https://spypharm.com/boehringers-ingelheims-survodutide-shows-liver-fibrosis-improvement Thu, 13 Jun 2024 04:00:04 -0400 spectro https://spypharm.com/french-company-orano-med-opens-new-radiation-production-facility-near-indianapolis https://spypharm.com/french-company-orano-med-opens-new-radiation-production-facility-near-indianapolis Sun, 09 Jun 2024 04:00:06 -0400 spectro https://spypharm.com/fda-advisory-committee-raises-concerns-about-eli-lillys-alzheimers-drug-donanemab https://spypharm.com/fda-advisory-committee-raises-concerns-about-eli-lillys-alzheimers-drug-donanemab Sun, 09 Jun 2024 04:00:03 -0400 spectro https://spypharm.com/illumina-decides-to-spin-off-grail https://spypharm.com/illumina-decides-to-spin-off-grail Fri, 07 Jun 2024 04:00:10 -0400 spectro https://spypharm.com/fda-panel-will-examine-which-covid-strain-should-be-the-focus-of-a-new-vaccine https://spypharm.com/fda-panel-will-examine-which-covid-strain-should-be-the-focus-of-a-new-vaccine Fri, 07 Jun 2024 04:00:08 -0400 spectro https://spypharm.com/merck-modernas-cancer-vaccine-collaboration-yields-positive-results-in-mid-stage-follow-up-study https://spypharm.com/merck-modernas-cancer-vaccine-collaboration-yields-positive-results-in-mid-stage-follow-up-study Fri, 07 Jun 2024 04:00:06 -0400 spectro https://spypharm.com/h7-bird-flu-discovered-on-fourth-poultry-farm-in-australia https://spypharm.com/h7-bird-flu-discovered-on-fourth-poultry-farm-in-australia Fri, 07 Jun 2024 04:00:03 -0400 spectro https://spypharm.com/soterios-achieves-phase-2-success-for-alopecia-cream-as-an-alternative-to-jak-inhibitors https://spypharm.com/soterios-achieves-phase-2-success-for-alopecia-cream-as-an-alternative-to-jak-inhibitors Mon, 03 Jun 2024 04:00:08 -0400 spectro https://spypharm.com/new-astrazeneca-derived-antibiotic-eliminates-deadly-bacteria-preserves-beneficial-ones https://spypharm.com/new-astrazeneca-derived-antibiotic-eliminates-deadly-bacteria-preserves-beneficial-ones Mon, 03 Jun 2024 04:00:06 -0400 spectro https://spypharm.com/following-a-34-million-transaction-adhd-game-creator-akili-interactive-will-go-private https://spypharm.com/following-a-34-million-transaction-adhd-game-creator-akili-interactive-will-go-private Mon, 03 Jun 2024 04:00:03 -0400 spectro https://spypharm.com/amgens-biosimilar-of-astrazenecas-rare-blood-condition-therapy-gets-approved-by-the-us-fda https://spypharm.com/amgens-biosimilar-of-astrazenecas-rare-blood-condition-therapy-gets-approved-by-the-us-fda Sat, 01 Jun 2024 04:00:15 -0400 spectro https://spypharm.com/phase-3-trial-results-show-datopotamab-deruxtecan-has-positive-outcomes-in-lung-cancer-patients https://spypharm.com/phase-3-trial-results-show-datopotamab-deruxtecan-has-positive-outcomes-in-lung-cancer-patients Sat, 01 Jun 2024 04:00:13 -0400 spectro https://spypharm.com/vaccine-against-avian-influenza-proves-to-be-effective-in-laying-hens https://spypharm.com/vaccine-against-avian-influenza-proves-to-be-effective-in-laying-hens Sat, 01 Jun 2024 04:00:10 -0400 spectro https://spypharm.com/musks-neuralink-aiming-to-enroll-three-patients-in-brain-implant-research https://spypharm.com/musks-neuralink-aiming-to-enroll-three-patients-in-brain-implant-research Sat, 01 Jun 2024 04:00:08 -0400 spectro https://spypharm.com/jjs-antidepressant-shows-promising-sleep-results-in-trial https://spypharm.com/jjs-antidepressant-shows-promising-sleep-results-in-trial Sat, 01 Jun 2024 04:00:06 -0400 spectro https://spypharm.com/nordson-to-welcome-atrion-into-its-medical-and-fluid-solutions-segment-for-800-million https://spypharm.com/nordson-to-welcome-atrion-into-its-medical-and-fluid-solutions-segment-for-800-million Sat, 01 Jun 2024 04:00:03 -0400 spectro https://spypharm.com/gerresheimer-increases-the-capabilities-of-medical-systems-in-the-usa https://spypharm.com/gerresheimer-increases-the-capabilities-of-medical-systems-in-the-usa Thu, 30 May 2024 04:00:09 -0400 spectro https://spypharm.com/astrazeneca-daiichis-enhertu-phase-3-trial-demonstrates-overall-survival-benefit https://spypharm.com/astrazeneca-daiichis-enhertu-phase-3-trial-demonstrates-overall-survival-benefit Thu, 30 May 2024 04:00:06 -0400 spectro https://spypharm.com/neuren-phase-2-study-shows-pitt-hopkins-syndrome-promise https://spypharm.com/neuren-phase-2-study-shows-pitt-hopkins-syndrome-promise Thu, 30 May 2024 04:00:03 -0400 spectro https://spypharm.com/biogen-inks-115b-deal-to-acquire-hi-bio https://spypharm.com/biogen-inks-115b-deal-to-acquire-hi-bio Sun, 26 May 2024 04:00:06 -0400 spectro https://spypharm.com/risk-of-low-blood-sugar-identified-in-novo-nordisks-once-weekly-insulin-before-fda-review https://spypharm.com/risk-of-low-blood-sugar-identified-in-novo-nordisks-once-weekly-insulin-before-fda-review Sun, 26 May 2024 04:00:03 -0400 spectro https://spypharm.com/study-projects-effects-of-race-neutral-lung-testing https://spypharm.com/study-projects-effects-of-race-neutral-lung-testing Fri, 24 May 2024 04:00:10 -0400 spectro https://spypharm.com/vicores-ipf-drug-yields-positive-results-in-phase-2a-air-trial https://spypharm.com/vicores-ipf-drug-yields-positive-results-in-phase-2a-air-trial Fri, 24 May 2024 04:00:08 -0400 spectro https://spypharm.com/15-billion-cancer-drug-facility-to-be-built-by-astrazeneca-in-singapore https://spypharm.com/15-billion-cancer-drug-facility-to-be-built-by-astrazeneca-in-singapore Fri, 24 May 2024 04:00:05 -0400 spectro https://spypharm.com/endeavors-ipf-drug-linked-to-improved-lung-function-in-phase-2-study https://spypharm.com/endeavors-ipf-drug-linked-to-improved-lung-function-in-phase-2-study Fri, 24 May 2024 04:00:03 -0400 spectro https://spypharm.com/lillys-weekly-insulin-dose-matches-daily-injections-in-testing https://spypharm.com/lillys-weekly-insulin-dose-matches-daily-injections-in-testing Wed, 22 May 2024 04:00:08 -0400 spectro https://spypharm.com/ionis-and-biogen-drop-als-drug-after-early-to-mid-stage-study-failu https://spypharm.com/ionis-and-biogen-drop-als-drug-after-early-to-mid-stage-study-failu Wed, 22 May 2024 04:00:06 -0400 spectro https://spypharm.com/amgens-drug-for-small-cell-lung-cancer-receives-us-fda-approval https://spypharm.com/amgens-drug-for-small-cell-lung-cancer-receives-us-fda-approval Wed, 22 May 2024 04:00:03 -0400 spectro https://spypharm.com/medtronics-field-ablation-system-bags-approval-in-japan https://spypharm.com/medtronics-field-ablation-system-bags-approval-in-japan Sat, 18 May 2024 04:00:19 -0400 spectro https://spypharm.com/eisai-and-biogen-start-rolling-submissions-with-the-fda-for-their-infused-alzheimers-drug-leqembi https://spypharm.com/eisai-and-biogen-start-rolling-submissions-with-the-fda-for-their-infused-alzheimers-drug-leqembi Sat, 18 May 2024 04:00:14 -0400 spectro https://spypharm.com/roche-gets-fda-approval-for-the-hpv-self-test-in-the-us https://spypharm.com/roche-gets-fda-approval-for-the-hpv-self-test-in-the-us Sat, 18 May 2024 04:00:09 -0400 spectro https://spypharm.com/bristol-myers-cancer-cell-therapy-receives-fda-green-light https://spypharm.com/bristol-myers-cancer-cell-therapy-receives-fda-green-light Sat, 18 May 2024 04:00:03 -0400 spectro https://spypharm.com/5-fatalities-in-macrogenics-adc-trial https://spypharm.com/5-fatalities-in-macrogenics-adc-trial Tue, 14 May 2024 04:00:19 -0400 spectro https://spypharm.com/the-keytruda-regimen-study-by-merck-fails-to-reach-its-primary-goal https://spypharm.com/the-keytruda-regimen-study-by-merck-fails-to-reach-its-primary-goal Tue, 14 May 2024 04:00:13 -0400 spectro https://spypharm.com/pfizer-and-astrazeneca-unveil-plans-for-almost-1b-of-new-investments-in-france https://spypharm.com/pfizer-and-astrazeneca-unveil-plans-for-almost-1b-of-new-investments-in-france Tue, 14 May 2024 04:00:08 -0400 spectro https://spypharm.com/triomics-to-attempt-to-revolutionize-clinical-trials-for-cancer-patients https://spypharm.com/triomics-to-attempt-to-revolutionize-clinical-trials-for-cancer-patients Tue, 14 May 2024 04:00:02 -0400 spectro https://spypharm.com/jjs-novel-drug-device-combination-demonstrates-success-in-intermediate-bladder-cancer-trial https://spypharm.com/jjs-novel-drug-device-combination-demonstrates-success-in-intermediate-bladder-cancer-trial Fri, 10 May 2024 00:00:21 -0400 spectro https://spypharm.com/gossamer-and-chiesi-join-forces-for-the-development-of-their-pulmonary-arterial-hypertension-pah-drug https://spypharm.com/gossamer-and-chiesi-join-forces-for-the-development-of-their-pulmonary-arterial-hypertension-pah-drug Fri, 10 May 2024 00:00:15 -0400 spectro https://spypharm.com/a-little-boys-tragic-cardiac-arrest-puts-pfizers-phase-3-gene-therapy-experiment-on-hold https://spypharm.com/a-little-boys-tragic-cardiac-arrest-puts-pfizers-phase-3-gene-therapy-experiment-on-hold Fri, 10 May 2024 00:00:10 -0400 spectro https://spypharm.com/marina-acquisition-further-solidifies-novartiss-place-in-radiopharma-landscape https://spypharm.com/marina-acquisition-further-solidifies-novartiss-place-in-radiopharma-landscape Wed, 08 May 2024 00:00:21 -0400 spectro https://spypharm.com/mirvie-launches-preeclampsia-prevention-toolkit https://spypharm.com/mirvie-launches-preeclampsia-prevention-toolkit Wed, 08 May 2024 00:00:15 -0400 spectro https://spypharm.com/regeneron-and-lilly-struggle-with-clinical-objectives-after-market-focus-on-weight-reduction https://spypharm.com/regeneron-and-lilly-struggle-with-clinical-objectives-after-market-focus-on-weight-reduction Wed, 08 May 2024 00:00:09 -0400 spectro https://spypharm.com/neurobiotech-company-harmony-biosciences-pays-35-million-upfront-to-acquire-epygenix-and-its-epilepsy-drug https://spypharm.com/neurobiotech-company-harmony-biosciences-pays-35-million-upfront-to-acquire-epygenix-and-its-epilepsy-drug Thu, 02 May 2024 00:00:25 -0400 spectro https://spypharm.com/pfizers-hemophilia-gene-therapy-approved-by-the-fda https://spypharm.com/pfizers-hemophilia-gene-therapy-approved-by-the-fda Thu, 02 May 2024 00:00:20 -0400 spectro https://spypharm.com/newrons-schizophrenia-add-on-shows-success-in-improving-symptoms https://spypharm.com/newrons-schizophrenia-add-on-shows-success-in-improving-symptoms Thu, 02 May 2024 00:00:14 -0400 spectro https://spypharm.com/fda-approves-rare-illness-medication-xolremdi-by-x4 https://spypharm.com/fda-approves-rare-illness-medication-xolremdi-by-x4 Thu, 02 May 2024 00:00:08 -0400 spectro https://spypharm.com/aribio-receives-ema-go-ahead-for-phase-iii-clinical-trial-for-alzheimers https://spypharm.com/aribio-receives-ema-go-ahead-for-phase-iii-clinical-trial-for-alzheimers Tue, 30 Apr 2024 00:00:20 -0400 spectro https://spypharm.com/bristol-myers-invests-65-million-to-increase-its-portfolio-of-autoimmune-products https://spypharm.com/bristol-myers-invests-65-million-to-increase-its-portfolio-of-autoimmune-products Tue, 30 Apr 2024 00:00:14 -0400 spectro https://spypharm.com/amap-by-charles-river-to-work-towards-developing-alternatives-to-animal-testing https://spypharm.com/amap-by-charles-river-to-work-towards-developing-alternatives-to-animal-testing Tue, 30 Apr 2024 00:00:08 -0400 spectro https://spypharm.com/the-fda-cautions-against-adverse-reactions-linked-to-counterfeit-botox-injections https://spypharm.com/the-fda-cautions-against-adverse-reactions-linked-to-counterfeit-botox-injections Mon, 22 Apr 2024 00:00:18 -0400 spectro https://spypharm.com/cerevel-reports-phase-3-parkinsons-success https://spypharm.com/cerevel-reports-phase-3-parkinsons-success Mon, 22 Apr 2024 00:00:12 -0400 spectro https://spypharm.com/neumora-schizophrenia-therapy-on-hold-after-rabbits-face-convulsions https://spypharm.com/neumora-schizophrenia-therapy-on-hold-after-rabbits-face-convulsions Mon, 22 Apr 2024 00:00:07 -0400 spectro https://spypharm.com/with-its-squishy-synthetic-platelets-the-startup-selsym-seeks-to-reduce-risk-from-bleeding https://spypharm.com/with-its-squishy-synthetic-platelets-the-startup-selsym-seeks-to-reduce-risk-from-bleeding Thu, 18 Apr 2024 00:00:08 -0400 spectro https://spypharm.com/maat-touts-18-month-data-as-proof-of-microbiome-therapy-viability https://spypharm.com/maat-touts-18-month-data-as-proof-of-microbiome-therapy-viability Tue, 16 Apr 2024 00:00:15 -0400 spectro https://spypharm.com/fda-puts-neumoras-schizophrenia-medication-on-hold-because-of-rabbit-convulsions https://spypharm.com/fda-puts-neumoras-schizophrenia-medication-on-hold-because-of-rabbit-convulsions Tue, 16 Apr 2024 00:00:08 -0400 spectro https://spypharm.com/highridge-medical-zimvies-successful-spinout-of-its-spine-division https://spypharm.com/highridge-medical-zimvies-successful-spinout-of-its-spine-division Sat, 06 Apr 2024 00:00:15 -0400 spectro https://spypharm.com/eisai-and-biogens-injectable-alzehimer-drug-faces-setback-from-the-fda https://spypharm.com/eisai-and-biogens-injectable-alzehimer-drug-faces-setback-from-the-fda Sat, 06 Apr 2024 00:00:08 -0400 spectro https://spypharm.com/with-fda-clearance-akebias-vafseo-finally-has-a-chance-to-compete-in-the-us-chronic-renal-disease-market https://spypharm.com/with-fda-clearance-akebias-vafseo-finally-has-a-chance-to-compete-in-the-us-chronic-renal-disease-market Thu, 04 Apr 2024 00:00:20 -0400 spectro https://spypharm.com/regeneron-to-conduct-confirmatory-trials-for-odronextamab-for-fda-approval https://spypharm.com/regeneron-to-conduct-confirmatory-trials-for-odronextamab-for-fda-approval Thu, 04 Apr 2024 00:00:14 -0400 spectro https://spypharm.com/zeposia-medication-from-bristol-myers-squibb-falls-short-in-a-study-for-crohns-disease https://spypharm.com/zeposia-medication-from-bristol-myers-squibb-falls-short-in-a-study-for-crohns-disease Thu, 04 Apr 2024 00:00:08 -0400 spectro https://spypharm.com/fda-refuses-to-approve-regenerons-blood-cancer-medication https://spypharm.com/fda-refuses-to-approve-regenerons-blood-cancer-medication Fri, 29 Mar 2024 00:00:21 -0400 spectro https://spypharm.com/jj-bags-fda-approval-for-pulmonary-arterial-combo-tablet https://spypharm.com/jj-bags-fda-approval-for-pulmonary-arterial-combo-tablet Fri, 29 Mar 2024 00:00:15 -0400 spectro https://spypharm.com/olympus-joins-hands-with-american-lung-association-for-cancer-education https://spypharm.com/olympus-joins-hands-with-american-lung-association-for-cancer-education Fri, 29 Mar 2024 00:00:07 -0400 spectro https://spypharm.com/johnson-matthey-sells-medical-metal-unit-to-montagu-in-700m-deal https://spypharm.com/johnson-matthey-sells-medical-metal-unit-to-montagu-in-700m-deal Wed, 27 Mar 2024 00:00:17 -0400 spectro https://spypharm.com/fda-approves-takedas-iclusig-for-philadelphia-chromosome-positive-all https://spypharm.com/fda-approves-takedas-iclusig-for-philadelphia-chromosome-positive-all Wed, 27 Mar 2024 00:00:10 -0400 spectro https://spypharm.com/novo-nordisk-invests-560-million-to-increase-chinese-medicine-production https://spypharm.com/novo-nordisk-invests-560-million-to-increase-chinese-medicine-production Sat, 23 Mar 2024 00:00:17 -0400 spectro https://spypharm.com/hippocratic-ai-secures-53m-funding-from-general-catalyst-memorial-hermann-uhs-a16z-and-others https://spypharm.com/hippocratic-ai-secures-53m-funding-from-general-catalyst-memorial-hermann-uhs-a16z-and-others Sat, 23 Mar 2024 00:00:12 -0400 spectro https://spypharm.com/promising-phase-3-results-propel-bayers-menopause-drug-towards-approval https://spypharm.com/promising-phase-3-results-propel-bayers-menopause-drug-towards-approval Sat, 23 Mar 2024 00:00:07 -0400 spectro https://spypharm.com/astrazeneca-acquires-amolyt-pharma-expanding-into-rare-endocrinology https://spypharm.com/astrazeneca-acquires-amolyt-pharma-expanding-into-rare-endocrinology Thu, 21 Mar 2024 00:00:18 -0400 spectro https://spypharm.com/astrazenecas-2-billion-acquisition-of-fusion-pharmaceuticals-signals-surge-in-radiopharmaceutical-interest https://spypharm.com/astrazenecas-2-billion-acquisition-of-fusion-pharmaceuticals-signals-surge-in-radiopharmaceutical-interest Thu, 21 Mar 2024 00:00:12 -0400 spectro https://spypharm.com/no-proof-of-brain-injury-in-havana-syndrome-patients https://spypharm.com/no-proof-of-brain-injury-in-havana-syndrome-patients Thu, 21 Mar 2024 00:00:07 -0400 spectro https://spypharm.com/lexicon-pharmaceuticals-on-track-to-resubmit-sotagliflozin-for-type-1-diabetes-approval https://spypharm.com/lexicon-pharmaceuticals-on-track-to-resubmit-sotagliflozin-for-type-1-diabetes-approval Fri, 15 Mar 2024 00:00:27 -0400 spectro https://spypharm.com/city-of-hope-mustang-bios-car-t-therapy-shows-promising-phase-1-results https://spypharm.com/city-of-hope-mustang-bios-car-t-therapy-shows-promising-phase-1-results Fri, 15 Mar 2024 00:00:22 -0400 spectro https://spypharm.com/lexicon-set-to-resubmit-zynquista-for-type-1-diabetes-treatment-5-years-after-fda-rejection https://spypharm.com/lexicon-set-to-resubmit-zynquista-for-type-1-diabetes-treatment-5-years-after-fda-rejection Fri, 15 Mar 2024 00:00:17 -0400 spectro https://spypharm.com/pfizers-adcetris-shows-promise-in-extending-survival-for-lymphoma-patients https://spypharm.com/pfizers-adcetris-shows-promise-in-extending-survival-for-lymphoma-patients Fri, 15 Mar 2024 00:00:12 -0400 spectro https://spypharm.com/hilabs-completes-39-million-funding-round-as-company-embarks-on-next-stage-of-expansion https://spypharm.com/hilabs-completes-39-million-funding-round-as-company-embarks-on-next-stage-of-expansion Fri, 15 Mar 2024 00:00:07 -0400 spectro https://spypharm.com/eli-lillys-lebrikizumab-shows-promise-in-eczema-treatment-for-skin-of-color https://spypharm.com/eli-lillys-lebrikizumab-shows-promise-in-eczema-treatment-for-skin-of-color Wed, 13 Mar 2024 18:26:14 -0400 spectro https://spypharm.com/incyte-meets-midphase-skin-condition-trial-goal https://spypharm.com/incyte-meets-midphase-skin-condition-trial-goal Wed, 13 Mar 2024 18:26:09 -0400 spectro https://spypharm.com/fda-lifts-partial-hold-on-iovances-cancer-therapy-trial https://spypharm.com/fda-lifts-partial-hold-on-iovances-cancer-therapy-trial Thu, 07 Mar 2024 18:00:27 -0500 spectro https://spypharm.com/merck-kgaa-offers-16m-for-two-c4-degraders https://spypharm.com/merck-kgaa-offers-16m-for-two-c4-degraders Thu, 07 Mar 2024 18:00:23 -0500 spectro https://spypharm.com/semaglutide-shows-promise-in-treating-liver-fat-in-hiv-patients https://spypharm.com/semaglutide-shows-promise-in-treating-liver-fat-in-hiv-patients Thu, 07 Mar 2024 18:00:18 -0500 spectro https://spypharm.com/novalix-joins-hands-with-max-planck-institute-on-cancer-pact https://spypharm.com/novalix-joins-hands-with-max-planck-institute-on-cancer-pact Thu, 07 Mar 2024 18:00:14 -0500 spectro https://spypharm.com/gilead-explores-triple-target-t-cell-engagers-in-over-15b-merus-partnership https://spypharm.com/gilead-explores-triple-target-t-cell-engagers-in-over-15b-merus-partnership Thu, 07 Mar 2024 18:00:09 -0500 spectro https://spypharm.com/fda-approves-allecras-exblifep-for-urinary-tract-infections-rejects-venatorx-and-melintas-treatment https://spypharm.com/fda-approves-allecras-exblifep-for-urinary-tract-infections-rejects-venatorx-and-melintas-treatment Fri, 01 Mar 2024 18:00:10 -0500 spectro https://spypharm.com/agiliti-set-to-go-private-in-25b-deal-by-thl-partners https://spypharm.com/agiliti-set-to-go-private-in-25b-deal-by-thl-partners Fri, 01 Mar 2024 18:00:10 -0500 spectro https://spypharm.com/following-fda-rejection-astrazeneca-finally-gives-up-us-rights-to-roxadustat https://spypharm.com/following-fda-rejection-astrazeneca-finally-gives-up-us-rights-to-roxadustat Fri, 01 Mar 2024 18:00:10 -0500 spectro https://spypharm.com/rovis-expansion-in-pharmaceutical-production-with-moderna https://spypharm.com/rovis-expansion-in-pharmaceutical-production-with-moderna Fri, 01 Mar 2024 18:00:09 -0500 spectro https://spypharm.com/prolonged-epigenetic-suppression-in-mice-strengthens-argument-for-therapeutic-applications https://spypharm.com/prolonged-epigenetic-suppression-in-mice-strengthens-argument-for-therapeutic-applications Fri, 01 Mar 2024 18:00:09 -0500 spectro https://spypharm.com/study-shows-roches-xolair-diminishes-severe-food-allergic-reactions https://spypharm.com/study-shows-roches-xolair-diminishes-severe-food-allergic-reactions Wed, 28 Feb 2024 18:00:09 -0500 spectro https://spypharm.com/275-million-new-genetic-variants-discovered-by-researchers https://spypharm.com/275-million-new-genetic-variants-discovered-by-researchers Wed, 28 Feb 2024 18:00:09 -0500 spectro https://spypharm.com/bristol-myers-squibb-expands-irish-campus-with-400m-investment-in-drug-manufacturing https://spypharm.com/bristol-myers-squibb-expands-irish-campus-with-400m-investment-in-drug-manufacturing Wed, 28 Feb 2024 18:00:08 -0500 spectro https://spypharm.com/breakthrough-antibiotic-shows-promise-against-resistant-gonorrhea https://spypharm.com/breakthrough-antibiotic-shows-promise-against-resistant-gonorrhea Wed, 28 Feb 2024 18:00:08 -0500 spectro https://spypharm.com/rapt-pharma-clinical-trial-for-atopic-dermatitis-placed-on-hold https://spypharm.com/rapt-pharma-clinical-trial-for-atopic-dermatitis-placed-on-hold Sat, 24 Feb 2024 18:00:09 -0500 spectro https://spypharm.com/european-commission-approves-pfizers-velsipity-for-ulcerative-colitis-treatment https://spypharm.com/european-commission-approves-pfizers-velsipity-for-ulcerative-colitis-treatment Sat, 24 Feb 2024 18:00:09 -0500 spectro https://spypharm.com/astrazenecas-tagrisso-chemo-combination-bags-fda-approval https://spypharm.com/astrazenecas-tagrisso-chemo-combination-bags-fda-approval Sat, 24 Feb 2024 18:00:08 -0500 spectro https://spypharm.com/first-t-cell-treatment-for-a-solid-tumor-amtagvi-approved-by-the-fda-from-iovance https://spypharm.com/first-t-cell-treatment-for-a-solid-tumor-amtagvi-approved-by-the-fda-from-iovance Sat, 24 Feb 2024 18:00:08 -0500 spectro https://spypharm.com/new-player-latigo-in-pain-biotech-challenges-vertex https://spypharm.com/new-player-latigo-in-pain-biotech-challenges-vertex Tue, 20 Feb 2024 18:00:13 -0500 spectro https://spypharm.com/denali-sanofis-als-candidate-falls-short-in-mid-stage-study https://spypharm.com/denali-sanofis-als-candidate-falls-short-in-mid-stage-study Tue, 20 Feb 2024 18:00:12 -0500 spectro https://spypharm.com/setbacks-mount-for-gileads-magrolimab-trials-as-fda-enforces-partial-hold https://spypharm.com/setbacks-mount-for-gileads-magrolimab-trials-as-fda-enforces-partial-hold Tue, 20 Feb 2024 18:00:12 -0500 spectro https://spypharm.com/takeda-bags-fda-approval-for-esophagus-inflammation-therapy https://spypharm.com/takeda-bags-fda-approval-for-esophagus-inflammation-therapy Fri, 16 Feb 2024 18:00:09 -0500 spectro https://spypharm.com/trial-for-gritstones-barda-funded-covid-19-vaccine-delayed-due-to-production-issues https://spypharm.com/trial-for-gritstones-barda-funded-covid-19-vaccine-delayed-due-to-production-issues Fri, 16 Feb 2024 18:00:08 -0500 spectro https://spypharm.com/biotech-firm-lianbio-announces-winding-down-operations https://spypharm.com/biotech-firm-lianbio-announces-winding-down-operations Fri, 16 Feb 2024 18:00:08 -0500 spectro https://spypharm.com/csl-behrings-major-trial-ends-in-disappointment-after-drug-fails-to-reduce-risk-of-heart-disease https://spypharm.com/csl-behrings-major-trial-ends-in-disappointment-after-drug-fails-to-reduce-risk-of-heart-disease Wed, 14 Feb 2024 18:00:09 -0500 spectro https://spypharm.com/novo-set-to-acquire-catalent-plant-for-165b https://spypharm.com/novo-set-to-acquire-catalent-plant-for-165b Wed, 14 Feb 2024 18:00:09 -0500 spectro https://spypharm.com/in-an-attempt-to-treat-liver-illness-gilead-buys-cymabay-for-43-billion https://spypharm.com/in-an-attempt-to-treat-liver-illness-gilead-buys-cymabay-for-43-billion Wed, 14 Feb 2024 18:00:08 -0500 spectro https://spypharm.com/unlearn-secures-50-million-in-latest-funding-round https://spypharm.com/unlearn-secures-50-million-in-latest-funding-round Wed, 14 Feb 2024 18:00:08 -0500 spectro https://spypharm.com/jjs-autoimmune-drug-prospect-meets-phase-3-goal-inches-closer-to-approval https://spypharm.com/jjs-autoimmune-drug-prospect-meets-phase-3-goal-inches-closer-to-approval Thu, 08 Feb 2024 18:00:16 -0500 spectro https://spypharm.com/novartis-spends-27-billion-on-acquiring-morphosys https://spypharm.com/novartis-spends-27-billion-on-acquiring-morphosys Thu, 08 Feb 2024 18:00:16 -0500 spectro https://spypharm.com/gene-therapy-helps-five-out-of-six-deaf-children-regain-their-hearing https://spypharm.com/gene-therapy-helps-five-out-of-six-deaf-children-regain-their-hearing Wed, 31 Jan 2024 18:00:08 -0500 spectro https://spypharm.com/tecartus-labeling-update-causes-momentary-confusion-in-fda-oversight-of-car-t-therapy-safety https://spypharm.com/tecartus-labeling-update-causes-momentary-confusion-in-fda-oversight-of-car-t-therapy-safety Wed, 31 Jan 2024 18:00:08 -0500 spectro https://spypharm.com/novo-nordisk-increase-supply-of-wegovy https://spypharm.com/novo-nordisk-increase-supply-of-wegovy Wed, 31 Jan 2024 18:00:07 -0500 spectro https://spypharm.com/defender-pharmaceuticals-confronts-fda-setback-in-approval-journey-for-nasal-motion-sickness-gel https://spypharm.com/defender-pharmaceuticals-confronts-fda-setback-in-approval-journey-for-nasal-motion-sickness-gel Wed, 31 Jan 2024 18:00:07 -0500 spectro https://spypharm.com/sareptas-dmd-drug-off-to-a-solid-start-but-elevidys-problem-lingers https://spypharm.com/sareptas-dmd-drug-off-to-a-solid-start-but-elevidys-problem-lingers Wed, 31 Jan 2024 18:00:07 -0500 spectro https://spypharm.com/major-trial-testing-shows-a-reduction-in-pain-by-using-vertexs-non-opioid-medication https://spypharm.com/major-trial-testing-shows-a-reduction-in-pain-by-using-vertexs-non-opioid-medication Wed, 31 Jan 2024 18:00:06 -0500 spectro https://spypharm.com/novo-nordisk-stakes-255-million-to-acquire-another-obesity-asset https://spypharm.com/novo-nordisk-stakes-255-million-to-acquire-another-obesity-asset Thu, 25 Jan 2024 18:00:09 -0500 spectro https://spypharm.com/gileads-trodelvy-lung-cancer-trial-fails-to-increase-survival-leading-to-a-sell-off https://spypharm.com/gileads-trodelvy-lung-cancer-trial-fails-to-increase-survival-leading-to-a-sell-off Thu, 25 Jan 2024 18:00:08 -0500 spectro https://spypharm.com/sanofi-snags-rare-drug-inbrx-101-in-a-bid-to-pioneer-biotech-advancements https://spypharm.com/sanofi-snags-rare-drug-inbrx-101-in-a-bid-to-pioneer-biotech-advancements Thu, 25 Jan 2024 18:00:08 -0500 spectro https://spypharm.com/surrozen-abandons-ibd-treatment-szn-1326 https://spypharm.com/surrozen-abandons-ibd-treatment-szn-1326 Tue, 23 Jan 2024 18:00:09 -0500 spectro https://spypharm.com/am-pharma-begins-phase-2-trial-of-ilofotase-alfa-for-renal-damage-prevention https://spypharm.com/am-pharma-begins-phase-2-trial-of-ilofotase-alfa-for-renal-damage-prevention Tue, 23 Jan 2024 18:00:09 -0500 spectro https://spypharm.com/sun-and-taro-reach-an-agreement-on-348m-buyout-after-17-years https://spypharm.com/sun-and-taro-reach-an-agreement-on-348m-buyout-after-17-years Tue, 23 Jan 2024 18:00:09 -0500 spectro https://spypharm.com/balversa-receives-fda-approval-for-bladder-cancer-treatment https://spypharm.com/balversa-receives-fda-approval-for-bladder-cancer-treatment Tue, 23 Jan 2024 18:00:08 -0500 spectro https://spypharm.com/over-200-layoffs-planned-by-lonza-at-clinical-production-facility-in-california https://spypharm.com/over-200-layoffs-planned-by-lonza-at-clinical-production-facility-in-california Tue, 23 Jan 2024 18:00:08 -0500 spectro https://spypharm.com/disco-pharmaceuticals-unveils-surfaceome-mapping-for-enhanced-cancer-therapeutics https://spypharm.com/disco-pharmaceuticals-unveils-surfaceome-mapping-for-enhanced-cancer-therapeutics Wed, 17 Jan 2024 18:00:07 -0500 spectro https://spypharm.com/biontech-allocates-20-million-to-wuxi-for-two-preclinical-monoclonal-antibodies https://spypharm.com/biontech-allocates-20-million-to-wuxi-for-two-preclinical-monoclonal-antibodies Mon, 15 Jan 2024 18:00:06 -0500 spectro https://spypharm.com/alcons-strategic-move-ar-15512-breakthrough-in-dry-eye-treatment https://spypharm.com/alcons-strategic-move-ar-15512-breakthrough-in-dry-eye-treatment Sat, 13 Jan 2024 18:00:08 -0500 spectro https://spypharm.com/approval-granted-to-eisai-and-biogens-leqembi-for-alzheimers-treatment-in-china https://spypharm.com/approval-granted-to-eisai-and-biogens-leqembi-for-alzheimers-treatment-in-china Thu, 11 Jan 2024 18:00:07 -0500 spectro https://spypharm.com/harvard-researchers-find-improved-efficacy-against-retinal-disease-in-mice https://spypharm.com/harvard-researchers-find-improved-efficacy-against-retinal-disease-in-mice Thu, 11 Jan 2024 18:00:07 -0500 spectro https://spypharm.com/gsk-set-to-purchase-aiolos-bio-expand-respiratory-pipeline https://spypharm.com/gsk-set-to-purchase-aiolos-bio-expand-respiratory-pipeline Thu, 11 Jan 2024 18:00:07 -0500 spectro https://spypharm.com/novo-nordisk-forges-million-dollar-research-pacts-with-flagship-backed-biotechs-for-advanced-cardiometabolic-solutions https://spypharm.com/novo-nordisk-forges-million-dollar-research-pacts-with-flagship-backed-biotechs-for-advanced-cardiometabolic-solutions Tue, 09 Jan 2024 18:00:11 -0500 spectro https://spypharm.com/vertex-pharmaceuticals-halts-vx-880-diabetes-drug-trial-amid-unrelated-patient-deaths https://spypharm.com/vertex-pharmaceuticals-halts-vx-880-diabetes-drug-trial-amid-unrelated-patient-deaths Tue, 09 Jan 2024 18:00:10 -0500 spectro https://spypharm.com/merck-to-acquire-harpoon-therapeutics-in-a-deal-worth-680m https://spypharm.com/merck-to-acquire-harpoon-therapeutics-in-a-deal-worth-680m Tue, 09 Jan 2024 18:00:10 -0500 spectro https://spypharm.com/bayers-drug-for-menopausal-relief-demonstrates-positive-results-in-advanced-clinical-trial https://spypharm.com/bayers-drug-for-menopausal-relief-demonstrates-positive-results-in-advanced-clinical-trial Tue, 09 Jan 2024 18:00:10 -0500 spectro https://spypharm.com/successful-phase-3-trials-propel-innovents-mazdutide-into-chinas-obesity-market https://spypharm.com/successful-phase-3-trials-propel-innovents-mazdutide-into-chinas-obesity-market Tue, 09 Jan 2024 18:00:09 -0500 spectro https://spypharm.com/in-phase-2-head-to-head-comparison-curevos-shingles-vaccine-is-equivalent-to-gsks-shingrix https://spypharm.com/in-phase-2-head-to-head-comparison-curevos-shingles-vaccine-is-equivalent-to-gsks-shingrix Tue, 09 Jan 2024 18:00:09 -0500 spectro https://spypharm.com/global-approval-in-the-future-for-astrazenecas-infant-rsv-immunization-drug-beyfortus https://spypharm.com/global-approval-in-the-future-for-astrazenecas-infant-rsv-immunization-drug-beyfortus Fri, 05 Jan 2024 18:00:07 -0500 spectro https://spypharm.com/roche-study-finds-novel-antibiotic-targets-drug-resistant-bacteria https://spypharm.com/roche-study-finds-novel-antibiotic-targets-drug-resistant-bacteria Fri, 05 Jan 2024 18:00:06 -0500 spectro https://spypharm.com/novartis-signs-a-100-million-upfront-gene-therapy-agreement-with-voyager https://spypharm.com/novartis-signs-a-100-million-upfront-gene-therapy-agreement-with-voyager Fri, 05 Jan 2024 18:00:06 -0500 spectro https://spypharm.com/roche-buys-point-of-care-technology-platform-from-lumiradx https://spypharm.com/roche-buys-point-of-care-technology-platform-from-lumiradx Wed, 03 Jan 2024 18:00:08 -0500 spectro https://spypharm.com/otsuka-and-ionis-pharmaceuticals-partner-for-hereditary-angioedema-treatment https://spypharm.com/otsuka-and-ionis-pharmaceuticals-partner-for-hereditary-angioedema-treatment Fri, 22 Dec 2023 18:00:16 -0500 spectro https://spypharm.com/gilead-sciences-secures-exclusive-rights-in-848-million-deal-with-compugen-for-innovative-cancer-therapy https://spypharm.com/gilead-sciences-secures-exclusive-rights-in-848-million-deal-with-compugen-for-innovative-cancer-therapy Fri, 22 Dec 2023 18:00:16 -0500 spectro https://spypharm.com/pivotal-bio-venture-partners-closes-389-million-fund-totaling-689-million-in-commitments https://spypharm.com/pivotal-bio-venture-partners-closes-389-million-fund-totaling-689-million-in-commitments Fri, 22 Dec 2023 18:00:16 -0500 spectro https://spypharm.com/gsk-returns-to-hansoh-and-pays-185-million-upfront-for-an-additional-adc https://spypharm.com/gsk-returns-to-hansoh-and-pays-185-million-upfront-for-an-additional-adc Fri, 22 Dec 2023 18:00:15 -0500 spectro https://spypharm.com/compass-unveils-safety-data-for-psilocybin-phase-2-ptsd-study https://spypharm.com/compass-unveils-safety-data-for-psilocybin-phase-2-ptsd-study Fri, 22 Dec 2023 18:00:15 -0500 spectro https://spypharm.com/sanofi-forced-to-abandon-lead-adc-tusamitamab-ravtansine-after-phase-3-trial-disappointment https://spypharm.com/sanofi-forced-to-abandon-lead-adc-tusamitamab-ravtansine-after-phase-3-trial-disappointment Fri, 22 Dec 2023 18:00:15 -0500 spectro https://spypharm.com/fda-approves-wainua-for-rare-disease-treatment https://spypharm.com/fda-approves-wainua-for-rare-disease-treatment Fri, 22 Dec 2023 18:00:14 -0500 spectro https://spypharm.com/ionis-and-astrazeneca-drug-gains-fda-approval-for-hereditary-transthyretin-amyloidosis https://spypharm.com/ionis-and-astrazeneca-drug-gains-fda-approval-for-hereditary-transthyretin-amyloidosis Fri, 22 Dec 2023 18:00:14 -0500 spectro https://spypharm.com/abbvie-to-shell-out-87b-to-purchase-cerevel https://spypharm.com/abbvie-to-shell-out-87b-to-purchase-cerevel Fri, 22 Dec 2023 18:00:14 -0500 spectro https://spypharm.com/jazz-pharmaceuticals-faces-setback-in-jzp150-phase-ii-trial-for-ptsd-treatment https://spypharm.com/jazz-pharmaceuticals-faces-setback-in-jzp150-phase-ii-trial-for-ptsd-treatment Fri, 22 Dec 2023 18:00:13 -0500 spectro https://spypharm.com/fda-receives-first-ever-mdma-drug-application https://spypharm.com/fda-receives-first-ever-mdma-drug-application Wed, 20 Dec 2023 18:00:12 -0500 spectro https://spypharm.com/fda-places-carsgen-therapeutics-car-t-cell-therapies-on-clinical-hold-impacts-global-expansion-plans https://spypharm.com/fda-places-carsgen-therapeutics-car-t-cell-therapies-on-clinical-hold-impacts-global-expansion-plans Mon, 18 Dec 2023 18:00:05 -0500 spectro https://spypharm.com/bmj-investigation-shines-light-on-semaglutide-uk-marketing https://spypharm.com/bmj-investigation-shines-light-on-semaglutide-uk-marketing Mon, 18 Dec 2023 18:00:04 -0500 spectro https://spypharm.com/novo-nordisk-foundations-260m-initiative-targets-enhanced-respiratory-vaccines https://spypharm.com/novo-nordisk-foundations-260m-initiative-targets-enhanced-respiratory-vaccines Mon, 18 Dec 2023 10:51:34 -0500 spectro https://spypharm.com/checkpoint-therapeutics-faces-fda-setback-but-optimism-persists-for-skin-cancer-therapy https://spypharm.com/checkpoint-therapeutics-faces-fda-setback-but-optimism-persists-for-skin-cancer-therapy Mon, 18 Dec 2023 10:51:34 -0500 spectro https://spypharm.com/pharvaris-hereditary-angioedema-medication-reduces-attacks-in-the-wake-of-the-fda-hold https://spypharm.com/pharvaris-hereditary-angioedema-medication-reduces-attacks-in-the-wake-of-the-fda-hold Mon, 18 Dec 2023 10:51:34 -0500 spectro https://spypharm.com/unveiling-weight-regain-trends-in-eli-lillys-zepbound-study https://spypharm.com/unveiling-weight-regain-trends-in-eli-lillys-zepbound-study Mon, 18 Dec 2023 10:51:33 -0500 spectro https://spypharm.com/bristol-myers-opdivo-and-cisplatin-combination-achieves-breakthrough-in-initial-colorectal-cancer-treatment https://spypharm.com/bristol-myers-opdivo-and-cisplatin-combination-achieves-breakthrough-in-initial-colorectal-cancer-treatment Thu, 14 Dec 2023 18:00:07 -0500 spectro https://spypharm.com/poseidas-roche-backed-off-the-shelf-car-t-shows-promise-amid-fda-concerns https://spypharm.com/poseidas-roche-backed-off-the-shelf-car-t-shows-promise-amid-fda-concerns Thu, 14 Dec 2023 18:00:07 -0500 spectro https://spypharm.com/neuroone-grabs-fda-clearance-for-ablation-tech https://spypharm.com/neuroone-grabs-fda-clearance-for-ablation-tech Thu, 14 Dec 2023 18:00:07 -0500 spectro https://spypharm.com/fda-approves-gene-therapies-for-sickle-cell-treatment https://spypharm.com/fda-approves-gene-therapies-for-sickle-cell-treatment Thu, 14 Dec 2023 18:00:06 -0500 spectro https://spypharm.com/microscopic-super-bots-repair-neural-wound-model https://spypharm.com/microscopic-super-bots-repair-neural-wound-model Wed, 06 Dec 2023 18:00:19 -0500 spectro https://spypharm.com/lillys-jaypirca-leads-the-leukemia-trail-with-fda-approval https://spypharm.com/lillys-jaypirca-leads-the-leukemia-trail-with-fda-approval Wed, 06 Dec 2023 18:00:18 -0500 spectro https://spypharm.com/merus-faces-setback-following-interim-report-for-lung-cancer-therapy https://spypharm.com/merus-faces-setback-following-interim-report-for-lung-cancer-therapy Wed, 06 Dec 2023 18:00:18 -0500 spectro https://spypharm.com/mercks-evobrutinib-encounters-setbacks-in-ms-trials-amid-btk-inhibitor-challenges https://spypharm.com/mercks-evobrutinib-encounters-setbacks-in-ms-trials-amid-btk-inhibitor-challenges Wed, 06 Dec 2023 18:00:17 -0500 spectro https://spypharm.com/roches-27-billion-move-into-the-obesity-market-acquisition-of-carmot-therapeutics https://spypharm.com/roches-27-billion-move-into-the-obesity-market-acquisition-of-carmot-therapeutics Mon, 04 Dec 2023 18:00:22 -0500 spectro https://spypharm.com/lung-cancer-data-from-abbvie-paves-way-for-accelerated-adc-approval-falls-below-initial-benchmark https://spypharm.com/lung-cancer-data-from-abbvie-paves-way-for-accelerated-adc-approval-falls-below-initial-benchmark Sat, 02 Dec 2023 18:00:10 -0500 spectro https://spypharm.com/amgen-expands-amazon-partnership-to-seek-generative-ai-solutions https://spypharm.com/amgen-expands-amazon-partnership-to-seek-generative-ai-solutions Thu, 30 Nov 2023 18:00:11 -0500 spectro https://spypharm.com/roivant-bids-farewell-to-lupus-treatment-following-phase-2-failure https://spypharm.com/roivant-bids-farewell-to-lupus-treatment-following-phase-2-failure Thu, 30 Nov 2023 18:00:11 -0500 spectro https://spypharm.com/in-a-late-stage-trial-gsks-blood-cancer-medication-achieves-its-main-objective https://spypharm.com/in-a-late-stage-trial-gsks-blood-cancer-medication-achieves-its-main-objective Thu, 30 Nov 2023 18:00:10 -0500 spectro https://spypharm.com/gsk-drops-bowel-disease-asset-amid-immunology-unit-changes https://spypharm.com/gsk-drops-bowel-disease-asset-amid-immunology-unit-changes Tue, 28 Nov 2023 18:00:15 -0500 spectro https://spypharm.com/astrazenecas-strategic-leap-into-kras-g12d-with-chinese-biotech-collaboration https://spypharm.com/astrazenecas-strategic-leap-into-kras-g12d-with-chinese-biotech-collaboration Tue, 28 Nov 2023 18:00:14 -0500 spectro https://spypharm.com/novo-nordisk-set-to-slash-victoza-production-to-boost-ozempic-supply https://spypharm.com/novo-nordisk-set-to-slash-victoza-production-to-boost-ozempic-supply Fri, 24 Nov 2023 18:00:12 -0500 spectro https://spypharm.com/merck-to-purchase-caraway-therapeutics-for-over-600m https://spypharm.com/merck-to-purchase-caraway-therapeutics-for-over-600m Fri, 24 Nov 2023 18:00:12 -0500 spectro https://spypharm.com/nanostring-faces-setback-in-patent-infringement-case-against-genomics https://spypharm.com/nanostring-faces-setback-in-patent-infringement-case-against-genomics Fri, 24 Nov 2023 18:00:12 -0500 spectro https://spypharm.com/indexs-ulcerative-colitis-drug-experiences-failure-in-phase-3-review https://spypharm.com/indexs-ulcerative-colitis-drug-experiences-failure-in-phase-3-review Fri, 24 Nov 2023 18:00:11 -0500 spectro https://spypharm.com/novo-nordisk-announces-21-billion-commitment-to-france https://spypharm.com/novo-nordisk-announces-21-billion-commitment-to-france Fri, 24 Nov 2023 18:00:11 -0500 spectro https://spypharm.com/lilly-plans-to-construct-a-25-billion-manufacturing-facility-in-germany https://spypharm.com/lilly-plans-to-construct-a-25-billion-manufacturing-facility-in-germany Wed, 22 Nov 2023 18:00:11 -0500 spectro https://spypharm.com/setback-for-bayer-as-promising-anti-clotting-drug-trials-halted https://spypharm.com/setback-for-bayer-as-promising-anti-clotting-drug-trials-halted Wed, 22 Nov 2023 18:00:10 -0500 spectro https://spypharm.com/karuna-therapeutics-phase-1b-trial-results-reinforce-cardiovascular-safety-of-schizophrenia-treatment-karxt https://spypharm.com/karuna-therapeutics-phase-1b-trial-results-reinforce-cardiovascular-safety-of-schizophrenia-treatment-karxt Wed, 22 Nov 2023 18:00:10 -0500 spectro https://spypharm.com/fda-expresses-doubt-over-mercks-cough-candidate https://spypharm.com/fda-expresses-doubt-over-mercks-cough-candidate Sat, 18 Nov 2023 18:00:12 -0500 spectro https://spypharm.com/gilead-gives-arcellx-285-million-to-extend-agreement-for-bcma-cell-treatment https://spypharm.com/gilead-gives-arcellx-285-million-to-extend-agreement-for-bcma-cell-treatment Sat, 18 Nov 2023 18:00:11 -0500 spectro https://spypharm.com/teva-secures-100m-funding-to-expedite-schizophrenia-drug-development https://spypharm.com/teva-secures-100m-funding-to-expedite-schizophrenia-drug-development Thu, 16 Nov 2023 18:00:31 -0500 spectro https://spypharm.com/new-york-university-study-finds-prominent-breakthrough-for-pain-management-outperforms-pain-drug https://spypharm.com/new-york-university-study-finds-prominent-breakthrough-for-pain-management-outperforms-pain-drug Thu, 16 Nov 2023 18:00:30 -0500 spectro https://spypharm.com/pfizers-cost-cutting-measures-impact-uks-sandwich-site-leading-to-job-loss-for-500-employees https://spypharm.com/pfizers-cost-cutting-measures-impact-uks-sandwich-site-leading-to-job-loss-for-500-employees Thu, 16 Nov 2023 18:00:30 -0500 spectro https://spypharm.com/novo-says-weight-loss-alone-isnt-to-thank-for-wegovys-heart-benefits https://spypharm.com/novo-says-weight-loss-alone-isnt-to-thank-for-wegovys-heart-benefits Thu, 16 Nov 2023 18:00:30 -0500 spectro https://spypharm.com/selecta-and-cartesian-strengthen-funding-for-the-objectives-of-autoimmune-cell-treatment-in-reverse-merger https://spypharm.com/selecta-and-cartesian-strengthen-funding-for-the-objectives-of-autoimmune-cell-treatment-in-reverse-merger Tue, 14 Nov 2023 18:00:05 -0500 spectro https://spypharm.com/astrazeneca-looking-for-another-liver-cancer-green-light-for-imfinzi https://spypharm.com/astrazeneca-looking-for-another-liver-cancer-green-light-for-imfinzi Tue, 14 Nov 2023 18:00:05 -0500 spectro https://spypharm.com/izervay-demonstrates-prolonged-efficacy-in-gather2-study-amidst-competitive-landscape https://spypharm.com/izervay-demonstrates-prolonged-efficacy-in-gather2-study-amidst-competitive-landscape Fri, 10 Nov 2023 18:00:15 -0500 spectro https://spypharm.com/vor-bios-adc-therapy-shows-encouraging-engraftment-with-reduced-toxicity https://spypharm.com/vor-bios-adc-therapy-shows-encouraging-engraftment-with-reduced-toxicity Fri, 10 Nov 2023 18:00:14 -0500 spectro https://spypharm.com/astrazeneca-abandons-phase-2-sickle-cell-medication-and-pays-185-million-to-rejoin-the-oral-obesity-gold-rush-market https://spypharm.com/astrazeneca-abandons-phase-2-sickle-cell-medication-and-pays-185-million-to-rejoin-the-oral-obesity-gold-rush-market Fri, 10 Nov 2023 18:00:14 -0500 spectro https://spypharm.com/after-success-with-its-babysat-system-owlet-gains-fda-clearance-for-its-dream-sock https://spypharm.com/after-success-with-its-babysat-system-owlet-gains-fda-clearance-for-its-dream-sock Fri, 10 Nov 2023 18:00:14 -0500 spectro https://spypharm.com/federal-court-rejects-alvogens-bid-for-fda-approval-of-bauschs-xifaxan-version https://spypharm.com/federal-court-rejects-alvogens-bid-for-fda-approval-of-bauschs-xifaxan-version Wed, 08 Nov 2023 18:00:17 -0500 spectro https://spypharm.com/atara-turns-to-pierre-fabre-in-huge-640m-t-cell-deal https://spypharm.com/atara-turns-to-pierre-fabre-in-huge-640m-t-cell-deal Wed, 08 Nov 2023 18:00:15 -0500 spectro https://spypharm.com/bd-launches-new-needle-free-blood-collection-tool https://spypharm.com/bd-launches-new-needle-free-blood-collection-tool Wed, 08 Nov 2023 18:00:14 -0500 spectro https://spypharm.com/medeor-therapeutics-innovative-kidney-transplant-cell-therapy-shows-promising-results https://spypharm.com/medeor-therapeutics-innovative-kidney-transplant-cell-therapy-shows-promising-results Sat, 04 Nov 2023 20:00:12 -0400 spectro https://spypharm.com/kronos-trims-staff-by-19-for-phase-12-solid-tumor-drug https://spypharm.com/kronos-trims-staff-by-19-for-phase-12-solid-tumor-drug Sat, 04 Nov 2023 20:00:11 -0400 spectro https://spypharm.com/astrazenecas-zibotentan-granted-new-life-in-ckd-trial https://spypharm.com/astrazenecas-zibotentan-granted-new-life-in-ckd-trial Sat, 04 Nov 2023 20:00:11 -0400 spectro https://spypharm.com/fda-advisors-greenlight-first-crispr-based-therapy-with-confidence-in-off-target-tests https://spypharm.com/fda-advisors-greenlight-first-crispr-based-therapy-with-confidence-in-off-target-tests Thu, 02 Nov 2023 20:00:35 -0400 spectro https://spypharm.com/c4-therapeutics-abandons-cancer-program-and-awaits-payment-from-betta https://spypharm.com/c4-therapeutics-abandons-cancer-program-and-awaits-payment-from-betta Thu, 02 Nov 2023 20:00:35 -0400 spectro https://spypharm.com/40-of-patients-respond-to-decipheras-tumor-fighting-oral-medication-setting-up-for-2024-submission https://spypharm.com/40-of-patients-respond-to-decipheras-tumor-fighting-oral-medication-setting-up-for-2024-submission Thu, 02 Nov 2023 20:00:35 -0400 spectro https://spypharm.com/gsks-jemperli-meets-survival-goal-in-endometrial-cancer-trial https://spypharm.com/gsks-jemperli-meets-survival-goal-in-endometrial-cancer-trial Tue, 31 Oct 2023 20:00:08 -0400 spectro https://spypharm.com/merck-invests-169-million-for-selective-parp1-medication https://spypharm.com/merck-invests-169-million-for-selective-parp1-medication Tue, 31 Oct 2023 20:00:08 -0400 spectro https://spypharm.com/belgium-considers-short-term-prohibition-of-novos-ozempic-weight-loss-drug https://spypharm.com/belgium-considers-short-term-prohibition-of-novos-ozempic-weight-loss-drug Fri, 27 Oct 2023 20:00:16 -0400 spectro https://spypharm.com/astrazenecas-self-administered-flu-vaccine-inches-closer-to-fda-green-light https://spypharm.com/astrazenecas-self-administered-flu-vaccine-inches-closer-to-fda-green-light Fri, 27 Oct 2023 20:00:16 -0400 spectro https://spypharm.com/enginzyme-utilizes-biocatalysis-to-manufacture-essential-component-for-mrna-vaccines https://spypharm.com/enginzyme-utilizes-biocatalysis-to-manufacture-essential-component-for-mrna-vaccines Fri, 27 Oct 2023 20:00:14 -0400 spectro https://spypharm.com/merck-eliminates-two-preclinical-kelun-programs-to-reduce-its-adc-pipeline https://spypharm.com/merck-eliminates-two-preclinical-kelun-programs-to-reduce-its-adc-pipeline Wed, 25 Oct 2023 20:00:23 -0400 spectro https://spypharm.com/roivant-to-sell-gut-disease-drug-to-roche-in-deal-over-7b https://spypharm.com/roivant-to-sell-gut-disease-drug-to-roche-in-deal-over-7b Wed, 25 Oct 2023 20:00:23 -0400 spectro https://spypharm.com/roche-invests-7-billion-to-compete-with-merck-in-the-bowel-disease-market https://spypharm.com/roche-invests-7-billion-to-compete-with-merck-in-the-bowel-disease-market Wed, 25 Oct 2023 20:00:23 -0400 spectro https://spypharm.com/merck-co-invests-heavily-in-promising-antibody-drug-conjugates-adcs https://spypharm.com/merck-co-invests-heavily-in-promising-antibody-drug-conjugates-adcs Sat, 21 Oct 2023 20:00:05 -0400 spectro https://spypharm.com/basilea-spends-2-million-to-acquire-clinical-stage-antifungal https://spypharm.com/basilea-spends-2-million-to-acquire-clinical-stage-antifungal Sat, 21 Oct 2023 20:00:05 -0400 spectro https://spypharm.com/siemens-healthineers-qureai-partnership-aims-to-enhance-tuberculosis-diagnosis-using-ai https://spypharm.com/siemens-healthineers-qureai-partnership-aims-to-enhance-tuberculosis-diagnosis-using-ai Sat, 21 Oct 2023 20:00:04 -0400 spectro https://spypharm.com/nkartas-landmark-fda-approval-propels-expansion-of-cell-therapy-into-lupus-treatment https://spypharm.com/nkartas-landmark-fda-approval-propels-expansion-of-cell-therapy-into-lupus-treatment Thu, 19 Oct 2023 20:00:16 -0400 spectro https://spypharm.com/gilead-to-invest-100-million-in-assembly-bio-in-return-for-all-current-and-future-programs https://spypharm.com/gilead-to-invest-100-million-in-assembly-bio-in-return-for-all-current-and-future-programs Thu, 19 Oct 2023 20:00:16 -0400 spectro https://spypharm.com/novo-nordisks-strategic-move-to-acquire-kbp-biosciences-promising-kidney-disease-drug https://spypharm.com/novo-nordisks-strategic-move-to-acquire-kbp-biosciences-promising-kidney-disease-drug Tue, 17 Oct 2023 20:00:06 -0400 spectro https://spypharm.com/roches-fenebrutinib-breakthrough-in-multiple-sclerosis-treatment-and-blood-brain-barrier-penetration https://spypharm.com/roches-fenebrutinib-breakthrough-in-multiple-sclerosis-treatment-and-blood-brain-barrier-penetration Tue, 17 Oct 2023 20:00:06 -0400 spectro https://spypharm.com/omeros-discontinues-renal-disease-phase-3-treatment-post-interim-review-failure https://spypharm.com/omeros-discontinues-renal-disease-phase-3-treatment-post-interim-review-failure Tue, 17 Oct 2023 20:00:05 -0400 spectro https://spypharm.com/roches-spark-joins-forces-with-splicebio-for-innovative-inherited-retinal-disease-solutions https://spypharm.com/roches-spark-joins-forces-with-splicebio-for-innovative-inherited-retinal-disease-solutions Tue, 17 Oct 2023 20:00:05 -0400 spectro https://spypharm.com/ultragenyx-and-mereos-genetic-treatment-slashes-bone-fractures-by-almost-70 https://spypharm.com/ultragenyx-and-mereos-genetic-treatment-slashes-bone-fractures-by-almost-70 Tue, 17 Oct 2023 20:00:05 -0400 spectro https://spypharm.com/philips-launches-new-platform-to-improve-health-monitoring https://spypharm.com/philips-launches-new-platform-to-improve-health-monitoring Fri, 13 Oct 2023 20:00:15 -0400 spectro https://spypharm.com/after-a-5-month-hold-fda-finally-clears-pepgens-myotonic-dystrophy-therapy https://spypharm.com/after-a-5-month-hold-fda-finally-clears-pepgens-myotonic-dystrophy-therapy Fri, 13 Oct 2023 20:00:14 -0400 spectro https://spypharm.com/labcorp-unveils-breakthrough-blood-test-for-alzheimers-diagnosis-and-neurodegenerative-disease-detection https://spypharm.com/labcorp-unveils-breakthrough-blood-test-for-alzheimers-diagnosis-and-neurodegenerative-disease-detection Fri, 13 Oct 2023 20:00:14 -0400 spectro https://spypharm.com/mercks-keytruda-achieves-overall-survival-goals-in-early-lung-cancer https://spypharm.com/mercks-keytruda-achieves-overall-survival-goals-in-early-lung-cancer Fri, 13 Oct 2023 20:00:14 -0400 spectro https://spypharm.com/15-million-investment-to-compete-in-the-eczema-challenge-alongside-amgen-and-sanofi https://spypharm.com/15-million-investment-to-compete-in-the-eczema-challenge-alongside-amgen-and-sanofi Fri, 13 Oct 2023 20:00:13 -0400 spectro https://spypharm.com/fda-rejects-alnylams-expanded-approval-request-for-rna-drug-patisiran-in-rare-heart-condition https://spypharm.com/fda-rejects-alnylams-expanded-approval-request-for-rna-drug-patisiran-in-rare-heart-condition Mon, 09 Oct 2023 20:00:15 -0400 spectro https://spypharm.com/bms-to-acquire-mirati-in-a-bid-to-diversify-oncology-portfolio https://spypharm.com/bms-to-acquire-mirati-in-a-bid-to-diversify-oncology-portfolio Mon, 09 Oct 2023 20:00:15 -0400 spectro https://spypharm.com/gsk-collaborates-with-chinese-giant-zhifei-on-a-3-billion-shingrix-project https://spypharm.com/gsk-collaborates-with-chinese-giant-zhifei-on-a-3-billion-shingrix-project Mon, 09 Oct 2023 20:00:15 -0400 spectro https://spypharm.com/zeiss-and-boehringer-ingelheim-have-formed-an-ai-backed-alliance https://spypharm.com/zeiss-and-boehringer-ingelheim-have-formed-an-ai-backed-alliance Thu, 05 Oct 2023 20:00:14 -0400 spectro https://spypharm.com/novartis-receives-great-reviews-for-iptacon-phase-3-performance https://spypharm.com/novartis-receives-great-reviews-for-iptacon-phase-3-performance Thu, 05 Oct 2023 20:00:14 -0400 spectro https://spypharm.com/fda-imposes-partial-clinical-hold-on-innate-pharmas-lymphoma-program-following-safety-concerns https://spypharm.com/fda-imposes-partial-clinical-hold-on-innate-pharmas-lymphoma-program-following-safety-concerns Thu, 05 Oct 2023 20:00:13 -0400 spectro https://spypharm.com/fractyls-glp-1-obesity-gene-therapy-performs-well-in-weight-loss-for-mice https://spypharm.com/fractyls-glp-1-obesity-gene-therapy-performs-well-in-weight-loss-for-mice Thu, 05 Oct 2023 20:00:13 -0400 spectro https://spypharm.com/fda-grants-authorization-to-invitae-dna-test-to-identify-cancer-predisposition https://spypharm.com/fda-grants-authorization-to-invitae-dna-test-to-identify-cancer-predisposition Thu, 05 Oct 2023 20:00:13 -0400 spectro https://spypharm.com/takeda-wagers-580m-on-acurastems-als-treatments https://spypharm.com/takeda-wagers-580m-on-acurastems-als-treatments Fri, 29 Sep 2023 20:00:06 -0400 spectro https://spypharm.com/gilead-abruptly-halts-phase-3-leukemia-trial-following-disappointing-data https://spypharm.com/gilead-abruptly-halts-phase-3-leukemia-trial-following-disappointing-data Fri, 29 Sep 2023 20:00:05 -0400 spectro https://spypharm.com/roche-pays-ionis-60-million-for-rna-targeting-alzheimers-and-huntingtons-disease-programs https://spypharm.com/roche-pays-ionis-60-million-for-rna-targeting-alzheimers-and-huntingtons-disease-programs Fri, 29 Sep 2023 20:00:05 -0400 spectro https://spypharm.com/fda-approves-ryzumvi-for-pharmacologically-induced-mydriasis-in-the-us https://spypharm.com/fda-approves-ryzumvi-for-pharmacologically-induced-mydriasis-in-the-us Fri, 29 Sep 2023 20:00:05 -0400 spectro https://spypharm.com/overcoming-age-related-challenges-in-nanodrug-delivery-for-pediatric-cancer-patients https://spypharm.com/overcoming-age-related-challenges-in-nanodrug-delivery-for-pediatric-cancer-patients Wed, 27 Sep 2023 20:00:08 -0400 spectro https://spypharm.com/60-degrees-pharmaceuticals-halts-tafenoquine-covid-19-trial-in-response-to-fda-recommendations https://spypharm.com/60-degrees-pharmaceuticals-halts-tafenoquine-covid-19-trial-in-response-to-fda-recommendations Wed, 27 Sep 2023 20:00:08 -0400 spectro https://spypharm.com/phase-3-trial-data-for-astellass-ga-drug-yielded-positive-results https://spypharm.com/phase-3-trial-data-for-astellass-ga-drug-yielded-positive-results Wed, 27 Sep 2023 20:00:08 -0400 spectro https://spypharm.com/morphics-emerald-1-trial-for-ulcerative-colitis-disappoints https://spypharm.com/morphics-emerald-1-trial-for-ulcerative-colitis-disappoints Wed, 27 Sep 2023 20:00:07 -0400 spectro https://spypharm.com/ionis-sees-success-in-lipid-reduction-phase-3-trial https://spypharm.com/ionis-sees-success-in-lipid-reduction-phase-3-trial Wed, 27 Sep 2023 20:00:07 -0400 spectro https://spypharm.com/sanofi-divests-11-cns-medications-to-pharmanovia-in-a-strategic-slimming-down-move https://spypharm.com/sanofi-divests-11-cns-medications-to-pharmanovia-in-a-strategic-slimming-down-move Thu, 21 Sep 2023 20:00:32 -0400 spectro https://spypharm.com/cgm-connected-app-feature-for-type-2-diabetes-patients-unveiled-by-abbott-and-weightwatchers https://spypharm.com/cgm-connected-app-feature-for-type-2-diabetes-patients-unveiled-by-abbott-and-weightwatchers Thu, 21 Sep 2023 20:00:31 -0400 spectro https://spypharm.com/with-the-trials-success-abbvie-prepares-botox-for-a-different-aesthetic-use https://spypharm.com/with-the-trials-success-abbvie-prepares-botox-for-a-different-aesthetic-use Thu, 21 Sep 2023 20:00:31 -0400 spectro https://spypharm.com/fresh-tracks-set-to-dissolve-with-no-buyer-in-the-pipeline https://spypharm.com/fresh-tracks-set-to-dissolve-with-no-buyer-in-the-pipeline Thu, 21 Sep 2023 20:00:31 -0400 spectro https://spypharm.com/ucbs-psoriasis-drug-application-faces-a-further-fda-delay https://spypharm.com/ucbs-psoriasis-drug-application-faces-a-further-fda-delay Thu, 21 Sep 2023 20:00:30 -0400 spectro https://spypharm.com/promising-bp-nell-peg-compound-may-protect-astronauts-from-rapid-bone-loss-in-space https://spypharm.com/promising-bp-nell-peg-compound-may-protect-astronauts-from-rapid-bone-loss-in-space Thu, 21 Sep 2023 20:00:30 -0400 spectro https://spypharm.com/fda-gives-green-light-to-gsks-innovative-bone-cancer-drug-validating-billion-dollar-investment https://spypharm.com/fda-gives-green-light-to-gsks-innovative-bone-cancer-drug-validating-billion-dollar-investment Tue, 19 Sep 2023 20:00:15 -0400 spectro https://spypharm.com/bms-terminates-two-mid-stage-and-four-early-stage-clinical-initiatives https://spypharm.com/bms-terminates-two-mid-stage-and-four-early-stage-clinical-initiatives Tue, 19 Sep 2023 20:00:15 -0400 spectro https://spypharm.com/kroger-health-joins-hands-with-performance-kitchen-to-provide-medically-tailored-food https://spypharm.com/kroger-health-joins-hands-with-performance-kitchen-to-provide-medically-tailored-food Tue, 19 Sep 2023 20:00:14 -0400 spectro https://spypharm.com/blackstones-250-million-investment-in-ex-novartis-assets-pays-off https://spypharm.com/blackstones-250-million-investment-in-ex-novartis-assets-pays-off Tue, 19 Sep 2023 20:00:14 -0400 spectro https://spypharm.com/biontech-receives-90-million-from-cepi-partnership https://spypharm.com/biontech-receives-90-million-from-cepi-partnership Tue, 19 Sep 2023 20:00:14 -0400 spectro https://spypharm.com/scientists-successfully-grow-part-human-part-pig-kidneys-to-solve-transplant-crisis https://spypharm.com/scientists-successfully-grow-part-human-part-pig-kidneys-to-solve-transplant-crisis Fri, 15 Sep 2023 20:00:05 -0400 spectro https://spypharm.com/fda-issues-warning-to-8-companies-selling-illegal-eye-drugs https://spypharm.com/fda-issues-warning-to-8-companies-selling-illegal-eye-drugs Fri, 15 Sep 2023 20:00:04 -0400 spectro https://spypharm.com/ahead-of-the-seasonal-spike-pfizer-and-biontechs-covid-vaccine-receives-fda-greenlight https://spypharm.com/ahead-of-the-seasonal-spike-pfizer-and-biontechs-covid-vaccine-receives-fda-greenlight Wed, 13 Sep 2023 20:00:06 -0400 spectro https://spypharm.com/novo-nordisks-wegovy-launch-in-uk-amid-competition https://spypharm.com/novo-nordisks-wegovy-launch-in-uk-amid-competition Wed, 13 Sep 2023 20:00:05 -0400 spectro https://spypharm.com/arbutus-halts-covid-19-rna-destabilization-projects-after-reviewing-early-preclinical-data https://spypharm.com/arbutus-halts-covid-19-rna-destabilization-projects-after-reviewing-early-preclinical-data Wed, 13 Sep 2023 20:00:05 -0400 spectro https://spypharm.com/moderna-forms-multi-billion-dollar-strategic-partnership-with-immatics https://spypharm.com/moderna-forms-multi-billion-dollar-strategic-partnership-with-immatics Mon, 11 Sep 2023 20:00:05 -0400 spectro https://spypharm.com/asensus-and-nvidia-collaborate-on-digital-surgical-ai https://spypharm.com/asensus-and-nvidia-collaborate-on-digital-surgical-ai Sat, 09 Sep 2023 20:00:04 -0400 spectro https://spypharm.com/trialbees-new-tool-aims-to-expedite-clinical-trial-recruitment-delays https://spypharm.com/trialbees-new-tool-aims-to-expedite-clinical-trial-recruitment-delays Sat, 09 Sep 2023 20:00:04 -0400 spectro https://spypharm.com/revvity-introduces-advanced-preclinical-imaging-tech-for-scientists-to-make-breakthroughs https://spypharm.com/revvity-introduces-advanced-preclinical-imaging-tech-for-scientists-to-make-breakthroughs Thu, 07 Sep 2023 20:00:10 -0400 spectro https://spypharm.com/nice-gives-chiesis-elfabrio-go-ahead https://spypharm.com/nice-gives-chiesis-elfabrio-go-ahead Tue, 05 Sep 2023 20:00:10 -0400 spectro https://spypharm.com/marketing-authorization-granted-for-abbvies-migraine-therapy-aquipta https://spypharm.com/marketing-authorization-granted-for-abbvies-migraine-therapy-aquipta Tue, 05 Sep 2023 20:00:10 -0400 spectro https://spypharm.com/bayer-banks-on-kerendias-potential-in-heart-failure-space https://spypharm.com/bayer-banks-on-kerendias-potential-in-heart-failure-space Tue, 05 Sep 2023 20:00:10 -0400 spectro https://spypharm.com/european-commission-approves-updated-pfizer-biontech-vaccine-for-omicron-xbb15-variant https://spypharm.com/european-commission-approves-updated-pfizer-biontech-vaccine-for-omicron-xbb15-variant Tue, 05 Sep 2023 20:00:09 -0400 spectro https://spypharm.com/amerisourcebergen-sheds-its-decades-old-identity-to-emerge-as-cencora https://spypharm.com/amerisourcebergen-sheds-its-decades-old-identity-to-emerge-as-cencora Fri, 01 Sep 2023 20:00:05 -0400 spectro https://spypharm.com/bristol-myers-secures-crucial-fda-approval-for-treatment-of-bone-marrow-disease https://spypharm.com/bristol-myers-secures-crucial-fda-approval-for-treatment-of-bone-marrow-disease Fri, 01 Sep 2023 20:00:05 -0400 spectro https://spypharm.com/beta-bionics-secures-100-million-for-artificial-pancreas-expansion-following-fda-approval https://spypharm.com/beta-bionics-secures-100-million-for-artificial-pancreas-expansion-following-fda-approval Fri, 01 Sep 2023 20:00:04 -0400 spectro https://spypharm.com/rite-aid-to-file-for-bankruptcy-to-reorganize-debt-and-stop-ongoing-drug-litigation https://spypharm.com/rite-aid-to-file-for-bankruptcy-to-reorganize-debt-and-stop-ongoing-drug-litigation Fri, 01 Sep 2023 20:00:04 -0400 spectro https://spypharm.com/novocures-ttfields-misses-the-mark-in-phase-3-ovarian-cancer-trial https://spypharm.com/novocures-ttfields-misses-the-mark-in-phase-3-ovarian-cancer-trial Wed, 30 Aug 2023 20:00:06 -0400 spectro https://spypharm.com/ge-healthcare-introduces-vscan-air-sl-a-handheld-ultrasound-device-for-rapid-cardiovascular-assessment https://spypharm.com/ge-healthcare-introduces-vscan-air-sl-a-handheld-ultrasound-device-for-rapid-cardiovascular-assessment Wed, 30 Aug 2023 20:00:06 -0400 spectro https://spypharm.com/bridgebio-explores-phase-3-acoramidis-data-in-depth https://spypharm.com/bridgebio-explores-phase-3-acoramidis-data-in-depth Wed, 30 Aug 2023 20:00:06 -0400 spectro https://spypharm.com/boston-scientifics-farapulse-system-irregular-heartbeat-treatment https://spypharm.com/boston-scientifics-farapulse-system-irregular-heartbeat-treatment Wed, 30 Aug 2023 20:00:05 -0400 spectro https://spypharm.com/self-adjusting-spinal-cord-stimulator-from-medtronic-receives-european-clearance https://spypharm.com/self-adjusting-spinal-cord-stimulator-from-medtronic-receives-european-clearance Wed, 30 Aug 2023 20:00:05 -0400 spectro https://spypharm.com/mallinckrodt-inching-closer-to-second-bankruptcy-filing https://spypharm.com/mallinckrodt-inching-closer-to-second-bankruptcy-filing Sat, 26 Aug 2023 20:00:05 -0400 spectro https://spypharm.com/roche-posts-encouraging-interim-study-results-for-a-lung-cancer-treatment https://spypharm.com/roche-posts-encouraging-interim-study-results-for-a-lung-cancer-treatment Sat, 26 Aug 2023 20:00:05 -0400 spectro https://spypharm.com/fda-panels-divided-verdict-delays-approval-for-medtronics-blood-pressure-device https://spypharm.com/fda-panels-divided-verdict-delays-approval-for-medtronics-blood-pressure-device Sat, 26 Aug 2023 20:00:04 -0400 spectro https://spypharm.com/regeneron-receives-fda-approval-for-longer-lasting-vision-loss-medication https://spypharm.com/regeneron-receives-fda-approval-for-longer-lasting-vision-loss-medication Thu, 24 Aug 2023 20:00:11 -0400 spectro https://spypharm.com/fda-greenlights-pfizers-rsv-vaccine-for-administration-during-pregnancy https://spypharm.com/fda-greenlights-pfizers-rsv-vaccine-for-administration-during-pregnancy Thu, 24 Aug 2023 20:00:11 -0400 spectro https://spypharm.com/spanish-pharmaceutical-company-serra-pamies-faces-ema-production-restrictions https://spypharm.com/spanish-pharmaceutical-company-serra-pamies-faces-ema-production-restrictions Thu, 24 Aug 2023 20:00:10 -0400 spectro https://spypharm.com/pfizer-slashes-enrollment-for-lyme-disease-trial-following-cro-trouble https://spypharm.com/pfizer-slashes-enrollment-for-lyme-disease-trial-following-cro-trouble Thu, 24 Aug 2023 20:00:10 -0400 spectro https://spypharm.com/hutchmed-eyes-drug-for-autoimmune-disease-approved-in-china-following-phase-3-success https://spypharm.com/hutchmed-eyes-drug-for-autoimmune-disease-approved-in-china-following-phase-3-success Tue, 22 Aug 2023 20:00:12 -0400 spectro https://spypharm.com/setbacks-continue-for-gileads-magrolimab-in-aml-studies-as-fda-places-partial-clinical-hold https://spypharm.com/setbacks-continue-for-gileads-magrolimab-in-aml-studies-as-fda-places-partial-clinical-hold Tue, 22 Aug 2023 20:00:12 -0400 spectro https://spypharm.com/novo-holdings-commits-290-million-to-fuel-innovation-and-expand-global-presence-of-sangon-biotech https://spypharm.com/novo-holdings-commits-290-million-to-fuel-innovation-and-expand-global-presence-of-sangon-biotech Tue, 22 Aug 2023 20:00:12 -0400 spectro https://spypharm.com/roche-and-exelixis-drug-combo-grabs-late-stage-prostate-cancer-victory https://spypharm.com/roche-and-exelixis-drug-combo-grabs-late-stage-prostate-cancer-victory Tue, 22 Aug 2023 20:00:11 -0400 spectro https://spypharm.com/celixirs-acquisition-by-ashington-innovation https://spypharm.com/celixirs-acquisition-by-ashington-innovation Sun, 20 Aug 2023 20:00:03 -0400 spectro https://spypharm.com/bluewind-medical-gets-fda-de-novo-clearance-for-neuromod-system https://spypharm.com/bluewind-medical-gets-fda-de-novo-clearance-for-neuromod-system Sun, 20 Aug 2023 20:00:03 -0400 spectro https://spypharm.com/two-year-study-shows-nevros-high-frequency-neurostimulation-reduces-diabetic-neuropathy-pain-by-80 https://spypharm.com/two-year-study-shows-nevros-high-frequency-neurostimulation-reduces-diabetic-neuropathy-pain-by-80 Fri, 18 Aug 2023 20:00:05 -0400 spectro https://spypharm.com/galactico-discontinues-lung-fibrosis-work-following-phase-2-failure https://spypharm.com/galactico-discontinues-lung-fibrosis-work-following-phase-2-failure Fri, 18 Aug 2023 20:00:04 -0400 spectro https://spypharm.com/living-fillings-the-future-of-regenerative-dentistry https://spypharm.com/living-fillings-the-future-of-regenerative-dentistry Fri, 18 Aug 2023 20:00:04 -0400 spectro https://spypharm.com/patient-death-causes-2seventy-bios-cd33-targeted-car-t-cell-therapy-trial-to-be-suspended https://spypharm.com/patient-death-causes-2seventy-bios-cd33-targeted-car-t-cell-therapy-trial-to-be-suspended Wed, 16 Aug 2023 20:00:10 -0400 spectro https://spypharm.com/fda-delays-decision-on-valnevas-chikungunya-vaccine-by-three-months-for-phase-4-negotiations https://spypharm.com/fda-delays-decision-on-valnevas-chikungunya-vaccine-by-three-months-for-phase-4-negotiations Wed, 16 Aug 2023 20:00:10 -0400 spectro https://spypharm.com/battery-and-shutdown-issues-lead-to-another-class-1-warning-for-getinges-heart-pump https://spypharm.com/battery-and-shutdown-issues-lead-to-another-class-1-warning-for-getinges-heart-pump Sat, 12 Aug 2023 20:00:04 -0400 spectro https://spypharm.com/hims-hers-expects-to-establish-a-weight-reduction-company-by-year-end https://spypharm.com/hims-hers-expects-to-establish-a-weight-reduction-company-by-year-end Thu, 10 Aug 2023 20:00:23 -0400 spectro https://spypharm.com/merck-and-ginkgo-forge-490-million-partnership-to-enhance-biologics-manufacturing-efficiency https://spypharm.com/merck-and-ginkgo-forge-490-million-partnership-to-enhance-biologics-manufacturing-efficiency Thu, 10 Aug 2023 20:00:22 -0400 spectro https://spypharm.com/phase-3-approval-of-novartis-btk-inhibitor-raises-concerns-about-dupixents-risks https://spypharm.com/phase-3-approval-of-novartis-btk-inhibitor-raises-concerns-about-dupixents-risks Thu, 10 Aug 2023 20:00:22 -0400 spectro https://spypharm.com/iveric-receives-fda-approval-for-geographic-atrophy-following-astellas-purchase https://spypharm.com/iveric-receives-fda-approval-for-geographic-atrophy-following-astellas-purchase Tue, 08 Aug 2023 20:00:06 -0400 spectro https://spypharm.com/sage-anticipates-job-cuts-and-project-scaling-down-following-zuranolones-mdd-rejection https://spypharm.com/sage-anticipates-job-cuts-and-project-scaling-down-following-zuranolones-mdd-rejection Tue, 08 Aug 2023 20:00:06 -0400 spectro https://spypharm.com/bristol-myers-squibb-launches-sotyktu-initiative-to-provide-a-comprehensive-insight-into-living-with-psoriasis https://spypharm.com/bristol-myers-squibb-launches-sotyktu-initiative-to-provide-a-comprehensive-insight-into-living-with-psoriasis Tue, 08 Aug 2023 20:00:05 -0400 spectro https://spypharm.com/novos-wegovy-successful-in-reducing-risk-of-cardiovascular-events-in-phase-3-trial https://spypharm.com/novos-wegovy-successful-in-reducing-risk-of-cardiovascular-events-in-phase-3-trial Tue, 08 Aug 2023 20:00:05 -0400 spectro https://spypharm.com/biogen-set-to-purchase-reata-in-a-deal-worth-over-7-billion https://spypharm.com/biogen-set-to-purchase-reata-in-a-deal-worth-over-7-billion Fri, 04 Aug 2023 20:00:05 -0400 spectro https://spypharm.com/amgens-lumakras-shows-promise-in-late-stage-colon-cancer-trial https://spypharm.com/amgens-lumakras-shows-promise-in-late-stage-colon-cancer-trial Fri, 04 Aug 2023 20:00:04 -0400 spectro https://spypharm.com/araviv-edercis-goals-are-derailed-by-a-phase-3-cancer-failure https://spypharm.com/araviv-edercis-goals-are-derailed-by-a-phase-3-cancer-failure Fri, 04 Aug 2023 20:00:04 -0400 spectro https://spypharm.com/fda-approves-terumos-reveos-system-automated-whole-blood-processing-to-address-platelet-shortage https://spypharm.com/fda-approves-terumos-reveos-system-automated-whole-blood-processing-to-address-platelet-shortage Fri, 04 Aug 2023 20:00:04 -0400 spectro https://spypharm.com/patient-enrollment-completed-for-nefecon-china-open-label-extension-study https://spypharm.com/patient-enrollment-completed-for-nefecon-china-open-label-extension-study Fri, 04 Aug 2023 20:00:04 -0400 spectro https://spypharm.com/astrazeneca-sells-assets-and-signs-gene-therapy-agreement-with-pfizer https://spypharm.com/astrazeneca-sells-assets-and-signs-gene-therapy-agreement-with-pfizer Wed, 02 Aug 2023 20:00:05 -0400 spectro https://spypharm.com/fda-reports-4-fatalities-associated-with-recalled-abiomed-impella-pumps https://spypharm.com/fda-reports-4-fatalities-associated-with-recalled-abiomed-impella-pumps Wed, 02 Aug 2023 20:00:05 -0400 spectro https://spypharm.com/quest-diagnostics-launches-blood-test-for-alzheimers-disease-aimed-at-general-consumers https://spypharm.com/quest-diagnostics-launches-blood-test-for-alzheimers-disease-aimed-at-general-consumers Wed, 02 Aug 2023 20:00:04 -0400 spectro https://spypharm.com/octapharmas-balfaxar-scores-fda-approval-for-warfarin-reversal-agent https://spypharm.com/octapharmas-balfaxar-scores-fda-approval-for-warfarin-reversal-agent Wed, 02 Aug 2023 20:00:04 -0400 spectro https://spypharm.com/gsks-hiv-prevention-drug-moves-toward-marketing-approval-in-europe https://spypharm.com/gsks-hiv-prevention-drug-moves-toward-marketing-approval-in-europe Sat, 29 Jul 2023 20:00:16 -0400 spectro https://spypharm.com/jj-gsk-indicate-cabenuva-preference-over-gilead-rival https://spypharm.com/jj-gsk-indicate-cabenuva-preference-over-gilead-rival Sat, 29 Jul 2023 20:00:16 -0400 spectro https://spypharm.com/glucotracks-cgm-implant-clears-first-feasibility-study https://spypharm.com/glucotracks-cgm-implant-clears-first-feasibility-study Sat, 29 Jul 2023 20:00:15 -0400 spectro https://spypharm.com/eli-lillys-obesity-drug-performs-well-in-two-late-stage-studies https://spypharm.com/eli-lillys-obesity-drug-performs-well-in-two-late-stage-studies Sat, 29 Jul 2023 20:00:15 -0400 spectro https://spypharm.com/vietnam-gives-green-light-to-first-african-swine-fever-vaccines https://spypharm.com/vietnam-gives-green-light-to-first-african-swine-fever-vaccines Thu, 27 Jul 2023 20:00:18 -0400 spectro https://spypharm.com/fda-approves-tarsus-xdemvy-the-first-treatment-for-a-prevalent-eyelid-condition https://spypharm.com/fda-approves-tarsus-xdemvy-the-first-treatment-for-a-prevalent-eyelid-condition Thu, 27 Jul 2023 20:00:18 -0400 spectro https://spypharm.com/verrica-scores-fda-approval-for-ycanth-at-the-cost-of-a-drop-in-share-value https://spypharm.com/verrica-scores-fda-approval-for-ycanth-at-the-cost-of-a-drop-in-share-value Thu, 27 Jul 2023 20:00:18 -0400 spectro https://spypharm.com/bavarian-nordic-fails-phase-3-trial-leaving-the-rsv-race https://spypharm.com/bavarian-nordic-fails-phase-3-trial-leaving-the-rsv-race Thu, 27 Jul 2023 20:00:18 -0400 spectro https://spypharm.com/miratis-kras-inhibitor-krazi-fails-to-make-it-in-europe https://spypharm.com/miratis-kras-inhibitor-krazi-fails-to-make-it-in-europe Tue, 25 Jul 2023 20:00:05 -0400 spectro https://spypharm.com/american-society-of-retinal-specialists-raise-concerns-regarding-apellis-pharmaceuticals-syfovre https://spypharm.com/american-society-of-retinal-specialists-raise-concerns-regarding-apellis-pharmaceuticals-syfovre Tue, 25 Jul 2023 20:00:05 -0400 spectro https://spypharm.com/fda-approves-memeds-bacteria-versus-virus-blood-test-to-the-point-of-care https://spypharm.com/fda-approves-memeds-bacteria-versus-virus-blood-test-to-the-point-of-care Tue, 25 Jul 2023 20:00:05 -0400 spectro https://spypharm.com/adc-therapeutics-terminates-zynlonta-study-after-fda-puts-a-hold https://spypharm.com/adc-therapeutics-terminates-zynlonta-study-after-fda-puts-a-hold Tue, 25 Jul 2023 20:00:05 -0400 spectro https://spypharm.com/novartis-acquires-dtx-pharma-in-a-deal-potentially-worth-1b https://spypharm.com/novartis-acquires-dtx-pharma-in-a-deal-potentially-worth-1b Fri, 21 Jul 2023 20:00:10 -0400 spectro https://spypharm.com/bridgebios-acoramidis-shows-positive-results-in-phase-3-trial-for-heart-disease https://spypharm.com/bridgebios-acoramidis-shows-positive-results-in-phase-3-trial-for-heart-disease Fri, 21 Jul 2023 20:00:10 -0400 spectro https://spypharm.com/alnylams-rnai-approach-reaches-the-biomarker-target https://spypharm.com/alnylams-rnai-approach-reaches-the-biomarker-target Fri, 21 Jul 2023 20:00:10 -0400 spectro https://spypharm.com/pharmaceutical-layoffs-begin-as-fibrogen-and-boston-sciences-cut-down-staff https://spypharm.com/pharmaceutical-layoffs-begin-as-fibrogen-and-boston-sciences-cut-down-staff Fri, 21 Jul 2023 20:00:09 -0400 spectro https://spypharm.com/sanofi-and-astrazeneca-receive-us-approval-for-infant-rsv-drug-beyfortus https://spypharm.com/sanofi-and-astrazeneca-receive-us-approval-for-infant-rsv-drug-beyfortus Fri, 21 Jul 2023 20:00:09 -0400 spectro https://spypharm.com/bms-expansion-into-neurodegeneration-space-with-95-million-partnership https://spypharm.com/bms-expansion-into-neurodegeneration-space-with-95-million-partnership Wed, 19 Jul 2023 20:00:11 -0400 spectro https://spypharm.com/expansion-of-novartis-beacon-of-hope-initiative https://spypharm.com/expansion-of-novartis-beacon-of-hope-initiative Wed, 19 Jul 2023 20:00:11 -0400 spectro https://spypharm.com/acumens-next-gen-leqembi-rival-shows-promise-in-early-alzheimers-data https://spypharm.com/acumens-next-gen-leqembi-rival-shows-promise-in-early-alzheimers-data Mon, 17 Jul 2023 20:00:04 -0400 spectro https://spypharm.com/incytes-opzelura-meets-primary-endpoint-in-eczema-trial-but-safety-concerns-persist https://spypharm.com/incytes-opzelura-meets-primary-endpoint-in-eczema-trial-but-safety-concerns-persist Sat, 15 Jul 2023 20:00:04 -0400 spectro https://spypharm.com/samsung-inks-391m-deal-with-novartis-amidst-plans-for-expanding-production-capacity https://spypharm.com/samsung-inks-391m-deal-with-novartis-amidst-plans-for-expanding-production-capacity Sat, 15 Jul 2023 20:00:04 -0400 spectro https://spypharm.com/fda-warning-letter-for-tablo-hemodialysis-system https://spypharm.com/fda-warning-letter-for-tablo-hemodialysis-system Sat, 15 Jul 2023 20:00:04 -0400 spectro https://spypharm.com/beigene-and-dualitybio-announce-partnership-for-solid-tumor-adc-therapy https://spypharm.com/beigene-and-dualitybio-announce-partnership-for-solid-tumor-adc-therapy Thu, 13 Jul 2023 20:00:04 -0400 spectro https://spypharm.com/fda-lifts-remaining-partial-ban-from-curis-late-stage-leukemia-trial https://spypharm.com/fda-lifts-remaining-partial-ban-from-curis-late-stage-leukemia-trial Thu, 13 Jul 2023 20:00:04 -0400 spectro https://spypharm.com/takeda-pulls-application-for-dengue-vaccine-qdenga https://spypharm.com/takeda-pulls-application-for-dengue-vaccine-qdenga Thu, 13 Jul 2023 20:00:04 -0400 spectro https://spypharm.com/opdivo-by-bristol-myers-shows-positive-results-in-phase-3-trial-for-bladder-cancer-patients https://spypharm.com/opdivo-by-bristol-myers-shows-positive-results-in-phase-3-trial-for-bladder-cancer-patients Thu, 13 Jul 2023 20:00:03 -0400 spectro https://spypharm.com/europe-conducting-review-of-potential-suicide-risks-associated-with-glp-1-drugs-from-novo-nordisk https://spypharm.com/europe-conducting-review-of-potential-suicide-risks-associated-with-glp-1-drugs-from-novo-nordisk Tue, 11 Jul 2023 20:00:04 -0400 spectro https://spypharm.com/tessa-therapeutics-dissolves-company https://spypharm.com/tessa-therapeutics-dissolves-company Tue, 11 Jul 2023 20:00:04 -0400 spectro https://spypharm.com/fda-grants-de-novo-clearance-to-renalytix-for-ai-based-kidney-disease-test https://spypharm.com/fda-grants-de-novo-clearance-to-renalytix-for-ai-based-kidney-disease-test Sun, 09 Jul 2023 20:00:03 -0400 spectro https://spypharm.com/jj-and-protagonist-therapeutics-move-oral-psoriasis-drug-to-phase-3-trial https://spypharm.com/jj-and-protagonist-therapeutics-move-oral-psoriasis-drug-to-phase-3-trial Sun, 09 Jul 2023 20:00:03 -0400 spectro https://spypharm.com/fda-dismisses-amneals-parkinsons-candidate https://spypharm.com/fda-dismisses-amneals-parkinsons-candidate Fri, 07 Jul 2023 20:00:09 -0400 spectro https://spypharm.com/astrazenecas-phase-iii-lung-cancer-data-fails-to-hit-the-mark-with-investors https://spypharm.com/astrazenecas-phase-iii-lung-cancer-data-fails-to-hit-the-mark-with-investors Wed, 05 Jul 2023 20:00:04 -0400 spectro https://spypharm.com/celltrion-healthcare-introduces-a-biosimilar-version-of-humira-called-yuflyma-in-the-us https://spypharm.com/celltrion-healthcare-introduces-a-biosimilar-version-of-humira-called-yuflyma-in-the-us Wed, 05 Jul 2023 20:00:04 -0400 spectro https://spypharm.com/promising-results-from-gelesis-study-show-stomach-filling-capsule-as-potential-alternative-to-glp-1s-for-weight-loss https://spypharm.com/promising-results-from-gelesis-study-show-stomach-filling-capsule-as-potential-alternative-to-glp-1s-for-weight-loss Sat, 01 Jul 2023 20:00:18 -0400 spectro https://spypharm.com/pfizers-breakthrough-treatment-for-severe-alopecia-areata-in-adolescents-receives-fda-approval https://spypharm.com/pfizers-breakthrough-treatment-for-severe-alopecia-areata-in-adolescents-receives-fda-approval Sat, 01 Jul 2023 20:00:17 -0400 spectro https://spypharm.com/vertex-and-lonza-join-forces-to-open-new-manufacturing-facility-for-the-formers-t1d-therapies https://spypharm.com/vertex-and-lonza-join-forces-to-open-new-manufacturing-facility-for-the-formers-t1d-therapies Sat, 01 Jul 2023 20:00:17 -0400 spectro https://spypharm.com/lilly-links-oral-obesity-drug-to-15-weight-loss-setting-the-bar-for-pfizer-in-a-competitive-battle https://spypharm.com/lilly-links-oral-obesity-drug-to-15-weight-loss-setting-the-bar-for-pfizer-in-a-competitive-battle Sat, 01 Jul 2023 20:00:17 -0400 spectro https://spypharm.com/intercept-abandons-nash-research-lays-off-staff-after-fda-rejection https://spypharm.com/intercept-abandons-nash-research-lays-off-staff-after-fda-rejection Tue, 27 Jun 2023 20:00:09 -0400 spectro https://spypharm.com/pfizer-to-stop-development-of-oral-obesity-drug-amidst-liver-safety-concerns https://spypharm.com/pfizer-to-stop-development-of-oral-obesity-drug-amidst-liver-safety-concerns Tue, 27 Jun 2023 20:00:09 -0400 spectro https://spypharm.com/pfizers-talzenna-gets-wider-approval-for-prostate-cancer-compared-to-astrazeneca-and-merck https://spypharm.com/pfizers-talzenna-gets-wider-approval-for-prostate-cancer-compared-to-astrazeneca-and-merck Sun, 25 Jun 2023 20:00:04 -0400 spectro https://spypharm.com/union-study-for-oral-orismilast-yields-positive-results-in-hidradenitis-suppurativa-patients https://spypharm.com/union-study-for-oral-orismilast-yields-positive-results-in-hidradenitis-suppurativa-patients Sun, 25 Jun 2023 20:00:03 -0400 spectro https://spypharm.com/acip-panel-set-to-vote-for-use-of-new-gsk-and-pfizer-rsv-shots https://spypharm.com/acip-panel-set-to-vote-for-use-of-new-gsk-and-pfizer-rsv-shots Sun, 25 Jun 2023 20:00:03 -0400 spectro https://spypharm.com/coherus-expands-beyond-biosimilars-with-65m-acquisition https://spypharm.com/coherus-expands-beyond-biosimilars-with-65m-acquisition Fri, 23 Jun 2023 20:00:04 -0400 spectro https://spypharm.com/fda-rejects-f2gs-nda-for-new-antifungal-drug-olorofim https://spypharm.com/fda-rejects-f2gs-nda-for-new-antifungal-drug-olorofim Wed, 21 Jun 2023 20:00:04 -0400 spectro https://spypharm.com/fda-gives-green-light-to-agepha-pharmas-heart-disease-drug https://spypharm.com/fda-gives-green-light-to-agepha-pharmas-heart-disease-drug Wed, 21 Jun 2023 20:00:04 -0400 spectro https://spypharm.com/astrazeneca-ditches-glp-1-drug-after-phase-1-setback-crushing-diabetes-hopes https://spypharm.com/astrazeneca-ditches-glp-1-drug-after-phase-1-setback-crushing-diabetes-hopes Wed, 21 Jun 2023 20:00:04 -0400 spectro https://spypharm.com/astrazeneca-joins-hands-with-new-chinese-biotech-to-work-on-hypercholesterolemia https://spypharm.com/astrazeneca-joins-hands-with-new-chinese-biotech-to-work-on-hypercholesterolemia Mon, 19 Jun 2023 20:00:05 -0400 spectro https://spypharm.com/aldeyras-allergic-conjunctivitis-treatment-shows-positive-results-in-phase-3-trial-amidst-wait-for-fda-approval https://spypharm.com/aldeyras-allergic-conjunctivitis-treatment-shows-positive-results-in-phase-3-trial-amidst-wait-for-fda-approval Mon, 19 Jun 2023 20:00:04 -0400 spectro https://spypharm.com/skyrizis-breakthrough-promising-results-in-ulcerative-colitis-maintenance-study-pave-the-way-for-fda-approval https://spypharm.com/skyrizis-breakthrough-promising-results-in-ulcerative-colitis-maintenance-study-pave-the-way-for-fda-approval Mon, 19 Jun 2023 20:00:04 -0400 spectro https://spypharm.com/mersana-hit-with-another-fda-hold-linked-to-patient-fatality https://spypharm.com/mersana-hit-with-another-fda-hold-linked-to-patient-fatality Sat, 17 Jun 2023 20:00:05 -0400 spectro https://spypharm.com/novartis-secures-32-billion-acquisition-of-chinook-to-enhance-kidney-disease-strategy https://spypharm.com/novartis-secures-32-billion-acquisition-of-chinook-to-enhance-kidney-disease-strategy Thu, 15 Jun 2023 20:00:03 -0400 spectro https://spypharm.com/astrazeneca-invests-85m-in-quell-for-one-and-done-cell-therapy-to-combat-type-1-diabetes https://spypharm.com/astrazeneca-invests-85m-in-quell-for-one-and-done-cell-therapy-to-combat-type-1-diabetes Tue, 13 Jun 2023 20:00:05 -0400 spectro https://spypharm.com/cue-health-racks-up-fdas-first-de-novo-nod-for-an-at-home-covid-test https://spypharm.com/cue-health-racks-up-fdas-first-de-novo-nod-for-an-at-home-covid-test Tue, 13 Jun 2023 20:00:05 -0400 spectro https://spypharm.com/commercial-excellence-summit-brings-together-leading-minds-to-solve-critical-commercial-problems https://spypharm.com/commercial-excellence-summit-brings-together-leading-minds-to-solve-critical-commercial-problems Tue, 13 Jun 2023 20:00:05 -0400 spectro https://spypharm.com/bon-secours-mercy-health-and-anthem-bcbs-lock-horns-over-contract-negotiations https://spypharm.com/bon-secours-mercy-health-and-anthem-bcbs-lock-horns-over-contract-negotiations Tue, 13 Jun 2023 20:00:04 -0400 spectro https://spypharm.com/gsks-adult-shot-arexvy-bags-european-approval https://spypharm.com/gsks-adult-shot-arexvy-bags-european-approval Fri, 09 Jun 2023 20:00:05 -0400 spectro https://spypharm.com/japanese-drugmaker-eisai-undergoing-investigation-for-ransomware-attack https://spypharm.com/japanese-drugmaker-eisai-undergoing-investigation-for-ransomware-attack Fri, 09 Jun 2023 20:00:05 -0400 spectro https://spypharm.com/fibrogens-dmd-drug-fails-phase-3-clinical-trial-adding-to-clinical-troubles https://spypharm.com/fibrogens-dmd-drug-fails-phase-3-clinical-trial-adding-to-clinical-troubles Fri, 09 Jun 2023 20:00:05 -0400 spectro https://spypharm.com/bayer-enters-agreement-with-acuitas-for-its-gene-editing-delivery-tech https://spypharm.com/bayer-enters-agreement-with-acuitas-for-its-gene-editing-delivery-tech Fri, 09 Jun 2023 20:00:04 -0400 spectro https://spypharm.com/arvinas-to-expand-development-of-resistance-busting-cancer-drug https://spypharm.com/arvinas-to-expand-development-of-resistance-busting-cancer-drug Fri, 09 Jun 2023 20:00:04 -0400 spectro https://spypharm.com/novartis-spinoff-sandoz-to-establish-hq-in-basel https://spypharm.com/novartis-spinoff-sandoz-to-establish-hq-in-basel Wed, 07 Jun 2023 20:00:14 -0400 spectro https://spypharm.com/novartis-drug-helps-stop-breast-cancers-return-in-a-large-study https://spypharm.com/novartis-drug-helps-stop-breast-cancers-return-in-a-large-study Wed, 07 Jun 2023 20:00:13 -0400 spectro https://spypharm.com/astrazeneca-adds-imfinzi-and-lynparza-to-ovarian-cancer-treatment https://spypharm.com/astrazeneca-adds-imfinzi-and-lynparza-to-ovarian-cancer-treatment Wed, 07 Jun 2023 20:00:13 -0400 spectro https://spypharm.com/fda-clears-narrow-use-of-prostate-cancer-therapy-lynparza https://spypharm.com/fda-clears-narrow-use-of-prostate-cancer-therapy-lynparza Wed, 07 Jun 2023 20:00:13 -0400 spectro https://spypharm.com/japanese-drugmaker-eisai-undergoingn-investigation-for-ransomware-attack https://spypharm.com/japanese-drugmaker-eisai-undergoingn-investigation-for-ransomware-attack Wed, 07 Jun 2023 20:00:10 -0400 spectro https://spypharm.com/fibrogens-dmd-drug-fails-phase-3-trial-adding-to-clinical-troubles https://spypharm.com/fibrogens-dmd-drug-fails-phase-3-trial-adding-to-clinical-troubles Wed, 07 Jun 2023 20:00:10 -0400 spectro https://spypharm.com/astrazenecas-andexxa-succeeds-in-postmarket-study-aims-for-full-approval https://spypharm.com/astrazenecas-andexxa-succeeds-in-postmarket-study-aims-for-full-approval Wed, 07 Jun 2023 20:00:10 -0400 spectro https://spypharm.com/pfizers-adult-rsv-vaccine-approval-sets-the-stage-for-an-imminent-launch https://spypharm.com/pfizers-adult-rsv-vaccine-approval-sets-the-stage-for-an-imminent-launch Sat, 03 Jun 2023 20:00:04 -0400 spectro https://spypharm.com/aridis-receives-fda-agreement-on-single-phase-3-study-for-ar-301 https://spypharm.com/aridis-receives-fda-agreement-on-single-phase-3-study-for-ar-301 Thu, 01 Jun 2023 20:00:10 -0400 spectro https://spypharm.com/eli-lilly-and-novo-nordisk-compete-in-the-obesity-drug-industry https://spypharm.com/eli-lilly-and-novo-nordisk-compete-in-the-obesity-drug-industry Thu, 01 Jun 2023 20:00:09 -0400 spectro https://spypharm.com/astrazenecas-imfinzi-lynparza-combo-shows-positive-trial-results-in-endometrial-cancer https://spypharm.com/astrazenecas-imfinzi-lynparza-combo-shows-positive-trial-results-in-endometrial-cancer Tue, 30 May 2023 20:00:05 -0400 spectro https://spypharm.com/jj-files-for-approval-of-carvykti-in-europe https://spypharm.com/jj-files-for-approval-of-carvykti-in-europe Tue, 30 May 2023 20:00:05 -0400 spectro https://spypharm.com/bristol-myers-data-makes-a-case-for-earlier-use-of-a-bone-marrow-disease-drug https://spypharm.com/bristol-myers-data-makes-a-case-for-earlier-use-of-a-bone-marrow-disease-drug Tue, 30 May 2023 20:00:05 -0400 spectro https://spypharm.com/miratis-phase-iii-sitravatinib-combo-trial-flops https://spypharm.com/miratis-phase-iii-sitravatinib-combo-trial-flops Tue, 30 May 2023 20:00:05 -0400 spectro https://spypharm.com/lexicon-pharmas-heart-failure-drug-receives-fda-nod https://spypharm.com/lexicon-pharmas-heart-failure-drug-receives-fda-nod Tue, 30 May 2023 20:00:04 -0400 spectro https://spypharm.com/amidst-covid-vaccine-supply-cuts-to-europe-moderna-expands-to-china https://spypharm.com/amidst-covid-vaccine-supply-cuts-to-europe-moderna-expands-to-china Tue, 30 May 2023 20:00:04 -0400 spectro https://spypharm.com/after-vaccines-moderna-moves-on-to-mrna-protein-replacement-therapy https://spypharm.com/after-vaccines-moderna-moves-on-to-mrna-protein-replacement-therapy Fri, 26 May 2023 20:00:05 -0400 spectro https://spypharm.com/elevatebio-closes-401m-series-d-round-inks-partnership-with-novo-nordisk https://spypharm.com/elevatebio-closes-401m-series-d-round-inks-partnership-with-novo-nordisk Fri, 26 May 2023 20:00:04 -0400 spectro https://spypharm.com/fda-delays-approval-of-duchenne-gene-therapy https://spypharm.com/fda-delays-approval-of-duchenne-gene-therapy Fri, 26 May 2023 20:00:04 -0400 spectro https://spypharm.com/novo-says-oral-version-of-obesity-drug-succeeds-in-large-study https://spypharm.com/novo-says-oral-version-of-obesity-drug-succeeds-in-large-study Fri, 26 May 2023 20:00:04 -0400 spectro https://spypharm.com/new-variation-of-the-once-obsolete-streptothricin-shows-positive-results-against-antibiotic-resistance https://spypharm.com/new-variation-of-the-once-obsolete-streptothricin-shows-positive-results-against-antibiotic-resistance Wed, 24 May 2023 20:00:13 -0400 spectro https://spypharm.com/krystal-biotech-gains-fda-green-light-for-skin-disorder-gene-therapy https://spypharm.com/krystal-biotech-gains-fda-green-light-for-skin-disorder-gene-therapy Wed, 24 May 2023 20:00:12 -0400 spectro